

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Erectile Dysfunction and Penile Rehabilitation after Pelvic Fracture – a Systematic Review and Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-045117
Article Type:	Original research
Date Submitted by the Author:	06-Oct-2020
Complete List of Authors:	Schmid, Florian; University Hospital Zurich, Urology; University of Zurich Faculty of Medicine, Held, Ulrike; Epidemiology, Biostatistics and Prevention Institute, Biostatistics Eberli, Daniel; University Hospital Zurich, Urology; University of Zurich Faculty of Medicine, Pape, Hans-Christoph; University Hospital Zurich, Trauma; University of Zurich Faculty of Medicine, Halvachizadeh, Sascha; University Hospital Zurich, Trauma; University of Zurich Faculty of Medicine,
Keywords:	ORTHOPAEDIC & TRAUMA SURGERY, Trauma management < ORTHOPAEDIC & TRAUMA SURGERY, UROLOGY, Male infertility < UROLOGY, Sexual dysfunction < UROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 **Erectile Dysfunction and Penile Rehabilitation after**
5
6
7 2 **Pelvic Fracture – a Systematic Review and Meta-**
8
9
10 3 **Analysis**
11
12
13
14 4
15
16
17 5 ***Systematic Review***
18
19
20 6
21
22 7
23
24
25 8 **Florian A. Schmid ¹, Ulrike Held ², Daniel Eberli ¹, Hans-Christoph Pape ³,**
26
27 9 **Sascha Halvachizadeh ³**
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

11 ¹ University Hospital Zurich, Department of Urology, University of Zurich, Zurich, Switzerland

12 ² Department of Biostatistics at Epidemiology, Biostatistics and Prevention Institute,
13 University of Zurich, Zurich, Switzerland

14 ³ University Hospital Zurich, Department of Trauma, University of Zurich, Zurich, Switzerland

17 Corresponding author:

18 Sascha Halvachizadeh, MD

19 Department of Trauma

20 University Hospital Zurich

21 Rämistrasse 100

22 8091 Zurich, Switzerland

23 Tel: +41 44 255 11 11

24 Email: sascha.halvachizadeh@usz.ch

26 Abstract word count: 294

27 Manuscript word count: 3207

28 **Abstract**

29 **Objective**

30 To investigate the rate of erectile dysfunction after pelvic ring fracture.

31 **Design**

32 Systematic review, and meta-analysis

33 **Methods**

34 A systematic literature search of the Cochrane, EMBASE, MEDLINE, Scopus and Web of
35 Science Library databases was conducted. Included were original studies performed on
36 humans assessing ED after PRF according the 5-item International Index of Erectile Function
37 (IIEF-5) questionnaire and fracture classification following Young & Burgess, Tile or AO/OTA.
38 Further, interventional cohort studies assessing the effect of penile rehabilitation therapy with
39 phosphodiesterase-5-inhibitors (PDE-5-I) on IIEF-5 scores compared before and after
40 treatment were included. Results were presented as forest plots of proportions of patients with
41 ED after PRF or mean changes on IIEF-5 questionnaires before and after penile rehabilitation.
42 Studies not included in the quantitative analysis were narratively summarized. Risk of bias
43 assessment was conducted using the revised tool for the Quality Assessment on Diagnostic
44 Accuracy studies (QUADAS-2).

45 **Results**

46 The systematic literature search retrieved 617 articles. Seven articles were included in the
47 qualitative analysis and the meta-analysis. Pooled proportions revealed 37% of patients with
48 ED after suffering any form of PRF (result on probability scale $pr = 0.37$, 95% CI: 0.26 to 0.50).
49 Patients after 3 months of penile rehabilitation therapy reported a higher IIEF-5 score than
50 before (change score [CS] = 6.5 points, 95% CI: 2.54 to 10.46, p -value = 0.0013).

51 **Conclusion**

1
2
3 52 Patients suffering from any type of PRF have an increased risk of developing ED. Oral intake
4
5 53 of PDE-5-I for the purpose of penile rehabilitation therapy increases IIEF-5 scores and may
6
7 54 relevantly influence QoL in these patients.
8
9

10 55 **Trial registration number**

11
12 56 PROSPERO ID: CRD42020169699
13

14 57 **Strengths and limitations**

- 15
16
17 58 • Despite strict definition of PRF and ED, there is still an inevitable variability due to the
18
19 59 heterogeneous methodological nature of available studies and study populations from
20
21 60 different centers worldwide
22
23 61 • Resulting from the lack of standardization, a broad variety of classifications for PRF
24
25 62 and different definitions and questionnaires for the evaluation of ED were used
26
27 63 • Included studies provide a certain risk o bias
28
29 64 • The included results were consistent across studies
30
31 65

66 Introduction

67 Pelvic ring fractures (PRF) result from high-energy injuries and are associated with devastating
68 acute and chronic complications as severe and life-threatening hemorrhage or chronic pain
69 and impaired ambulation ¹⁻⁵. The initial treatment of PRF is guided by the fracture morphology,
70 pathophysiologic reaction of the organism to the trauma and concomitant injuries ⁶⁻⁹. After
71 initial hemodynamic stabilization and fixation of the PRF, an interdisciplinary team-approach
72 aims to improve long-term outcomes and to reduce complications ^{10 11}. In male patients
73 suffering from PRF, erectile dysfunction (ED) is one of the main long-term complications. ED
74 ranks among the adverse effects after PRF that severely impair the quality of life (QoL) in these
75 patients, especially when urogenital damage is involved ¹²⁻¹⁴. The treatment of ED depends on
76 the underlying pathogenesis and on patient-specific factors – it ranges from psychological
77 behavior therapy and pharmacological support until surgical interventions ¹⁵. The incidence of
78 ED after PRF varies across the published literature, indicating a potentially high number of
79 missed cases. It further remains unclear, whether patients with PRF benefit from early
80 pharmacological penile rehabilitation therapy with phosphodiesterase-5-inhibitors (PDE-5-I).
81 Therefore, this meta-analysis aims to answer the following questions: A) Is the incidence of
82 ED associated with the severity of PRF? B) What is the treatment effect of penile rehabilitation
83 after PRF with the help of PDE-5-I? We hypothesize, that the rate of ED is associated with the
84 increasing severity of PRFs and that pharmacological penile rehabilitation improves blood
85 circulation in the pelvic organ region and therefore reduces the chances of persistent ED.

86 **Methods**

87 This study was conducted following the Preferred Reporting Items for Systematic Reviews and
88 Meta-analyses (PRISMA) guidelines ^{16 17}. It was recorded on PROSPERO, the prospective
89 register of systematic reviews, under the registration ID: CRD42020169699.

91 **Search strategy and definitions**

92 A scientific librarian and information expert, specialized in medical research, conducted a
93 systematic literature search of the Cochrane, EMBASE, MEDLINE, Scopus and Web of
94 Science Library databases. PRF are classified following Young and Burgess ¹⁸, Tile ¹⁹ or the
95 AO/OTA classification ²⁰. ED was evaluated based on the 5-item International Index of Erectile
96 Function (IIEF-5) questionnaire ^{21 22}. Presence of ED was defined as a score between 5 and
97 21 (severe-mild ED) according to results on IIEF-5 questionnaires. Categorization according
98 to the achieved IIEF-5 score leads to the following subgrouping: "Severe" (5-7 points),
99 "moderate" (8-11 points), "mild to moderate" (12-16 points), "mild" (17-21 points) and "no" (22-
100 25 points) ED ²³. The term "penile rehabilitation" refers to the treatment of ED with PDE-5-I.

102 **Inclusion / exclusion criteria**

103 Inclusion criteria were original studies performed on humans assessing ED after PRF written
104 in French, Spanish, Italian, German and English language. To increase comparability, we only
105 included articles that assessed ED based on IIEF-5 and classified the severity of PRF
106 accordingly (see above). We included interventional cohort studies assessing the effect of
107 PDE-5-I on ED after PRF with the reported change of the IIEF-5 scores prior and after PDE-
108 5-I treatment as main outcome parameter. Articles assessing secondary ED after treatment of
109 urethral injuries were excluded. Further, articles without full-text availability were excluded.
110 Case reports, case series, narrative reviews, expert opinions, editorials, book chapters,
111 conference abstracts, letters, commentaries, correspondences, in vitro and animal

1
2
3 112 experiments were completely excluded from the systematic review. The full search string is
4
5 113 shown in the *Appendix 1*.

6
7 114
8
9 115 **Data management**

10
11 116 The export of de-duplicated publications from all sources were saved in an EndNote library.
12
13 117 Two authors (FAS and SH) received the same library and independently screened and
14
15 118 assorted all articles within the publicly available web-tool Rayyan ²⁴.

16
17 119
18
19
20 120 **Study selection**

21
22
23 121 According to the PRISMA flow diagram, steps of screening were performed as follows ¹⁶: 1.)
24
25 122 title and abstract screening, 2.) full text screening, 3.) extraction and storage of data, 4.)
26
27 123 qualitative and quantitative evidence synthesis. After title and abstract screening, full texts
28
29 124 were obtained for formal inclusion or exclusion into our systematic review. Full text analysis
30
31 125 was performed independently by two authors (FAS and SH). Discrepancies were resolved by
32
33 126 consensus or, if necessary, until consensus was reached. Studies that did not provide the type
34
35 127 of PRF and the subsequent proportion of patients with ED, as well as no baseline scores of
36
37 128 IIEF-5 questionnaires (before PDE-5-I therapy) for the evaluation of penile rehabilitation, were
38
39 129 not included in the quantitative analysis. However, some of these studies were summarized in
40
41 130 a narrative way.

42
43 131
44
45
46 132 **Data extraction**

47
48
49 133 The following data was extracted from published articles: (i) general study information: author,
50
51 134 year, country, study design (i.e. prospective or retrospective); (ii) patient characteristics:
52
53 135 sample size, age, type of pelvic injury (category), follow-up time (months); (iii) outcome: rate
54
55 136 of patients with ED (proportion), mean or median IIEF-5 score (absolute values) either after
56
57 137 trauma and follow-up or before and after treatment, IIEF-5 category (categorical values);
58
59 138 associated injuries (iv): urogenital injuries (proportion) or urethral injury (proportion), other

1
2
3 139 injury sites (amount); treatment (v): medication (type of PDE-5-I), dosage (mg) and treatment
4
5 140 duration (months).

6
7 141 The data was extracted independently and in duplicate by two authors (FAS and SH) on
8
9 142 separate copies of an Excel spreadsheet. These were compared and discrepancies were
10
11 143 resolved by consensus.
12

13
14 144

15 16 17 145 **Risk of bias**

18
19
20 146 Risk of bias assessment was conducted using the revised tool for the Quality Assessment on
21
22 147 Diagnostic Accuracy studies (QUADAS-2)²⁵. Each study was assessed for risk of bias through
23
24 148 four key domains: patient selection, usage of standardized IIEF-5 questionnaires, grouping
25
26 149 into internationally accepted pelvic fracture classifications and flow & timing. For each domain,
27
28 150 the two authors (FAS and SH) independently assigned a rating of low, high or unclear risk of
29
30 151 bias. Again, discrepancies were resolved through discussion or until consensus was reached.
31

32
33 152

34 35 36 153 **Statistical analysis**

37
38
39 154 Descriptive statistics on study level were reported as means and proportions. For evidence
40
41 155 synthesis for continuous outcomes, means with standard deviations (SD) were used for
42
43 156 pooling in a random effects model. If studies reported means with standard errors (SE), the
44
45 157 SD was computed using the formula provided by the Cochrane Collaboration: $SD = SE * \sqrt{N}$
46
47 158 ²⁶. For studies which reported values as median with range or interquartile range (IQR), we
48
49 159 estimated the mean and SD according to the formulas by Wan et al.²⁷. To confirm the reliability
50
51 160 of these estimations, we performed them in duplicate using the formulas by Luo et al.²⁸, and
52
53 161 compared the results of the two methods. Both methods have in general shown good reliability
54
55 162 for these estimations, even in presence of deviation from the normal distribution²⁹. Evidence
56
57 163 synthesis for binary outcomes was done by dividing reported numbers of patients with the
58
59 164 condition over total number of patients in each study, and these proportions were used for

1
2
3 165 pooling in a random effects logistic regression model. The random effects model computes
4
5 166 exact 95% confidence intervals (CI) based on the binomial distribution for the overall effect.
6
7 167 Results were presented as forest plots of mean changes of IIEF-5 questionnaires before and
8
9 168 after penile rehabilitation, or proportions of patients with ED including 95% CI. In one forest
10
11 169 plot, studies were ordered by subtypes of pelvic ring fractures. To quantify heterogeneity, the
12
13 170 Q-test (total between-study variance), I^2 - (proportion of total variation) and H^2 -statistic (ratio of
14
15 171 total amount of variability and amount of sampling variance) was calculated for all meta-
16
17 172 analyses . All statistical analyses were performed using R (version 3.4.2) ³⁰.
18
19
20 173

174 Results

175 Study selection and characteristics

176 According to the systematic literature research and after removal of duplicates, 617 articles
177 were found. The initial screening process for title and abstract excluded 556 articles. The full-
178 text analysis of the remaining 61 articles led to the exclusion of further 54 articles. We included
179 four articles assessing the incidence of ED after PRF based on IIEF-5 and three articles
180 investigating the treatment effect of PDE-5-I on ED after PRF (*Figure 1*). Articles included for
181 qualitative and quantitative analysis were published between the years 2000 and 2019 and
182 were all retrospective cohort studies (*Table 1*).

184 Incidence of ED after PRF

185 The analysis for the incidence of ED after PRF included 181 male patients with mean age 42
186 years. Out of these, 65 patients (35.9%) reported ED based on IIEF-5 score of ≤ 21 points.
187 The mean follow-up was 24.01 ± 10.91 months. The overall mean IIEF-5 score was $20.01 \pm$
188 2.01 points. The rate of ED after anterior-posterior compression (APC) fracture or Type A
189 fractures was 29.27%. The rate of ED after lateral compression (LC) or Type B PRF was
190 17.86%. After vertical shear (VS) or Type C PRF 48% of patients suffered from ED. PRF with
191 associated pelvic fracture urethral injury (PFUI) led to a higher percentage of ED than PRF
192 without PFUI (58.6 % vs. 38.1%). Pooling the proportions with the random effects model
193 resulted in 37% of patients with ED after suffering any form of PRF (result on probability scale
194 $pr = 0.37$, 95% CI: 0.26 to 0.50). As a measure of heterogeneity, the percentage of variability
195 (I^2) was moderate with 44.2% (p -value = 0.021).

196
197 Elevated probabilities for the development of ED after PRF was described in Tile fractures type
198 B and C ($pr = 0.62$; 95% CI: 0.28 to 0.87 and $pr = 0.80$; 95% CI: 0.31 to 0.97, respectively) as
199 well as with injuries associated with PFUI ($pr = 0.59$; 95% CI: 0.40 to 0.75). Duramaz et al.

1
2
3 200 reported higher proportions of ED in patients with APC and VS (pr = 0.42; 95% CI: 0.18 to 0.69
4
5 201 and pr = 0.40; 95% CI: 0.21 to 0.62, respectively) compared to LC fractures (pr = 0.02; 95%
6
7 202 CI: 0.00 to 0.29) according Young & Burgess. Fanjalalaina and colleagues reported the highest
8
9 203 proportion of ED with 80% of patients affected after PRF Tile C (pr = 0.80; 95% CI: 0.31 to
10
11 204 0.97). The lowest proportion of ED was demonstrated by Duramaz et al. in LC fractures with
12
13 205 0% of patients developing ED after a follow up of 27 months (pr = 0.02; 95% CI: 0.00 to 0.29).
14
15 206 Further, the type A fractures presented by Fanjalalaina et al. and the overall chances to
16
17 207 develop ED in a combined group of A, B and C fractures from Malavaud reported all lower
18
19 208 probabilities than the studies of comparison (pr = 0.24; 95% CI: 0.12 to 0.43 and OR = 0.30;
20
21 209 95% CI: 0.17 to 0.46, respectively). For overall results, please see forest plot in *Figure 2*.
22
23
24 210

211 **Effect of penile rehabilitation in patients with PRF**

212 Three studies with cumulative 67 patients investigated the effect of penile rehabilitation using
213 PDE-5-I for the treatment of ED after PRF with concomitant PFUI. The mean age of patients
214 across studies was 33 years. Either Sildenafil (50 mg) or Tadalafil (5 mg) were used for a
215 treatment duration of three months. The mean IIEF-score after PRF and before treatment was
216 6.69 ± 1.16 points and increased to 13.3 ± 4.5 points after PDE-5-I treatment. There was strong
217 evidence that the IIEF-5 score in patients after penile rehabilitation therapy was higher than
218 the IIEF-5 score before treatment (change score [CS] = 6.5 points increase, 95% CI: 2.54 to
219 10.46, p-value = 0.0013). The largest difference in IIEF-5 scores before and after 3 months of
220 Tadalafil treatment (5 mg) was reported by Nieto et al. (CS = 10.75, 95% CI: 8.04 to 13.46).
221 Peng and colleagues published in 2014 the smallest effect of penile rehabilitation therapy after
222 3 months of Sildenafil (50 mg) with a statistically higher IIEF-score, comparing before and after
223 treatment (CS = 4.00, 95% CI: 3.01 to 4.99). A considerable heterogeneity was observed
224 between the studies in this meta-analysis, justifying the use of a random effects model ($I^2 =$
225 93%, $p < 0.0001$). For summarized results, please see forest plot in *Figure 3*.
226

227 **Study quality**

228 The assessment of study quality is depicted in *Figure 4*. The overall quality of the included
229 studies was low due to a rather high risk of bias. We found selection bias to be a concern for
230 more than half of the included studies. This was due to studies not following consecutive
231 recruitment, no or partial definition of inclusion and exclusion criteria as well as time and/or
232 place of recruitment. Either no or only sparse information was available on the different types
233 of fractures that were subdivided into groups of internationally accepted classifications. Finally
234 yet importantly, flow & timing of the study was associated with a high risk of bias in almost all
235 cases, except for Fanjalalaina and colleagues ³¹.

236 Discussion

237 PRF resulting from high-energy trauma is associated with increased mortality³, impaired QoL
238³²⁻³⁴ and concomitant injuries of pelvic organs³⁵. Amongst other adverse effects, ED is an
239 underestimated functional complication in male patients after PRF³⁶. The aim of this article
240 was to assess the rate of ED after PRF and the effect of pharmacological penile rehabilitation
241 with PDE-5-I on assessed, standardized IIEF-5 questionnaires. The following three points can
242 be regarded as quintessence of this systematic review and the underlying meta-analysis: A)
243 Males after PRF have a significant risk (37%) of developing any form of ED according to IIEF-5
244 scores, independent of injury severity. B) Pharmacological penile rehabilitation with PDE-5-I
245 improves the individual IIEF-5 score by 6.5 points after a consecutive treatment of 3 months
246 following injury in a male cohort with PRF and PFUI.

247
248 The rate of ED after PRF is subject of substantial research activities. In one of the first
249 published manuscripts dealing with this topic in 1975, King et al. reviewed 90 patients and
250 noted an incidence of 5-42% of ED after pelvic trauma, already claiming that ED was more
251 commonly associated with concomitant urethral injury³⁷. In 2007, Metze and colleagues
252 investigated the rate of ED after PRF in 77 men utilizing a the long version of the IIEF
253 questionnaire for evaluation: They reported 61% of patients with limitations in sexual function,
254 19% with persistent impairment and an increased risk of persistence with associated posterior
255 ring disruptions (Tile C)³⁸. The IIEF is known to be a simple questionnaire that meets
256 established criteria, is consistent and reliable regarding test-retest reproducibility. Its' validity
257 to evaluate improvement of EF after ED treatment is further justified³⁹. Another study noted
258 the rate of moderate and severe ED based on the IIEF-5 score to be 46.1%, increasing in line
259 with the complexity of the fractures (Tile B and C), whereas mild and moderate forms of ED
260 were present in 53.9% of patients affected from type A fractures⁴⁰. A recent publication
261 concluded, similar to our observed results, that APC and VS fractures according
262 Young&Burgess are more associated with ED in men and sexual dysfunction in both sexes,

1
2
3 263 than LC fractures ⁴¹. In a review article from Harwood and colleagues, the rate of ED after
4
5 264 pelvic fractures without PFUI ranges from 5 to 24% and from 9 to 72% with PFUI ⁴². They
6
7 265 discussed the broad variance of assessment tools for ED as well as concomitant injuries as
8
9 266 relevant reasons for the broad variability of the gathered data ⁴². Several studies investigated
10
11 267 the pathogenesis of ED following pelvic fractures, identifying vasculogenic ⁴³⁻⁴⁷, neurogenic ⁴³⁻
12
13 268 ^{46 48} and psychogenic ^{44 47} etiologies. One of the most commonly investigated risk factor for
14
15 269 developing ED following PRF is the presence and severity of urethral injuries as collateral
16
17 270 damage ^{13 46 49-51}. However, the management and the relevance of early vs. delayed surgical
18
19 271 or conservative treatment approaches after PFUI is still controversially discussed ⁵²⁻⁵⁵.
20
21 272 Excluding PFUI, the present study concludes an incidence of ED based on standardized IIEF-5
22
23 273 questionnaires of 41.5% ranging from 29.7 to 71.4%, whereas the broad variance of incidence
24
25 274 is mostly depending on injury severity. According to our meta-analysis, there is a visible trend
26
27 275 for an increased rate of ED among higher classifications of PRF injuries. The severity of PRFs
28
29 276 are associated with concomitant injuries such as vascular ⁵⁶, nerve ⁵⁷ as well as abdominal
30
31 277 and urogenital organ damage ³⁵. Wright and colleagues identified that patients with sacroiliac
32
33 278 fractures to have at least a four times higher risk for sexual and excretory dysfunction ⁵⁸.
34
35 279 Further, it has been demonstrated, that patients suffer from a decreased QoL after more
36
37 280 severe forms of PRFs ^{33 59 60}. All these risk factors, including higher trauma energy, are
38
39 281 therefore associated with the development of persistent ED ^{42 61}.
40
41
42
43 282
44
45 283 Strategies to treat ED as consequence of PRF include pharmacological, mechanical and
46
47 284 invasive treatment approaches. Initial attempts in Italy used Papaverine and Prostaglandin E1
48
49 285 as vasodilative, intracavernous injections ⁶². In 2004, Shenfield et al. treated patients with
50
51 286 ED after PFUI with 100mg oral Sildenafil (PDE-5-I) on demand for 3-6 months. Forty-seven
52
53 287 percent responded favorably to treatment, of which one third reported resumption of normal
54
55 288 spontaneous erections during the follow-up of 18 months ⁶³. Oral PDE-5-I therapy is regarded
56
57 289 as standard of care and serves as initial reference treatment in men suffering from ED ⁶⁴⁻⁶⁶.
58
59 290 Both Sildenafil and Tadalafil are commonly used representatives of PDE5-I in the treatment of

1
2
3 291 ED with comparable safety and efficacy⁶⁷. The management of concomitant injuries following
4
5 292 PRF includes the early diagnostics and exclusion or treatment of organic damages in order to
6
7 293 prevent or reduce the risk of ED^{13 14 42}. According the results of our meta-analysis, the
8
9 294 treatment with PDE-5-I increases the IIEF-5 score by 6.5 points in patients with ED after PRF
10
11 295 with urethral injury. However, it remains unclear whether it also supports the permanent
12
13 296 recovery of spontaneous erectile function. Similarly, the data for the efficacy of penile
14
15 297 rehabilitation after radical prostatectomy is still controversially discussed^{68 69}. The effect seems
16
17 298 to be ameliorated with a regular treatment regime compared to on-demand use of PDE-5-I in
18
19 299 patients with ED after radical prostatectomy⁷⁰. The current limited evidence demonstrates,
20
21 300 that daily oral intake of PDE-5-I seems to have also a relevant positive effect on ED in 55-88%
22
23 301 of patients after PRF with or without associated PFUI⁷¹⁻⁷⁴. Further, the efficacy of
24
25 302 pharmacological therapy can also be supported with mechanical aids, such as the use of
26
27 303 vacuum erection devices or low-intensity shock-wave therapy. Both have shown to ameliorate
28
29 304 IIEF-5 score and erection quality when used in combination with PDE-5-I, compared to stand-
30
31 305 alone treatment⁷⁵⁻⁷⁷. Finally, the implantation of penile prosthesis or revascularization surgery
32
33 306 are both regarded as last resort options in ED treatment of patients after perineal or pelvic
34
35 307 surgery or trauma⁷⁸.

38
39 308

40 41 309 **Conclusion**

42
43
44 310 Patients who suffer from PRF have an increased risk of developing ED, regardless of the
45
46 311 classification severity and the concomitant injuries. Early beginning of penile rehabilitation with
47
48 312 the pharmacological help of PDE-5-I on a daily basis and a treatment duration of at least 3
49
50 313 months may relevantly reduce ED after PRF and therefore ameliorate QoL in these patients.

314 **Acknowledgements**

315 We thank Dr. sc. nat. Martina Gosteli, scientific librarian at the main library from the University
316 of Zurich (Switzerland), for her precious efforts in performing a profound systematic literature
317 research regarding the topic.

318 **Conflicts of interest**

319 None of the authors has any conflicts of interest to declare

320 **Funding**

321 No external funding sources were utilized in conducting and completing this study.

322 **Author Statement**

323 FA and SH contributed equally to this work: They developed the research idea and led the
324 research team; both authors screened independently all articles, and found consent in cases
325 of disagreement, both authors extracted and analyzed the data; They wrote the original draft
326 of the manuscript

327 UH supported and supervised the methodology and the statistical analysis of the meta data;

328 UH read and reviewed the manuscript critically

329 DE and HCP supervised the entire project, provided the infrastructure for conducting this
330 research and critically reviewed the manuscript

331 **References**

- 332 1. Almahmoud K, Pfeifer R, Al-Kofahi K, et al. Impact of pelvic fractures on the early
333 clinical outcomes of severely injured trauma patients. *Eur J Trauma Emerg Surg*
334 2018;44(2):155-62. doi: 10.1007/s00068-016-0754-6
- 335 2. Pape HC, Zelle B, Lohse R, et al. Evaluation and outcome of patients after
336 polytrauma--can patients be recruited for long-term follow-up? *Injury*
337 2006;37(12):1197-203. doi: 10.1016/j.injury.2006.07.032
- 338 3. Aaran LHC, Him CK, Bong LK, et al. Outcome of Haemodynamically Unstable Open
339 Pelvic Fracture Patients Managed With "3-in-1" Pelvic Damage Control Protocol
340 in a Major Trauma Centre. *J Orthop Trauma Rehabil* 2018;25:62-68. doi:
341 10.1016/j.jotr.2017.10.002
- 342 4. Mann SM, Banaszek D, Lajkosz K, et al. High-energy trauma patients with pelvic
343 fractures: Management trends in Ontario, Canada. *Injury-Int J Care Inj*
344 2018;49(10):1830-40. doi: 10.1016/j.injury.2018.06.044
- 345 5. Matityahu A, Marmor M, Elson JK, et al. Acute complications of patients with pelvic
346 fractures after pelvic angiographic embolization. *Clinical Orthopaedics &*
347 *Related Research*;471(9):2906-11.
- 348 6. Giannoudis PV, Pape HC. Damage control orthopaedics in unstable pelvic ring
349 injuries. *Injury-Int J Care Inj* 2004;35(7):671-77. doi:
350 10.1016/j.injury.2004.03.003
- 351 7. Stahel PF, Burlew CC, Moore EE. Current trends in the management of
352 hemodynamically unstable pelvic ring injuries. *Curr Opin Crit Care*
353 2017;23(6):511-19. doi: 10.1097/MCC.0000000000000454 [published Online
354 First: 2017/11/03]
- 355 8. Papakostidis C, Kanakaris NK, Kontakis G, et al. Pelvic ring disruptions: treatment
356 modalities and analysis of outcomes. *Int Orthop* 2009;33(2):329-38. doi:
357 10.1007/s00264-008-0555-6 [published Online First: 2008/05/08]
- 358 9. Kuper MA, Trulson A, Stuby FM, et al. Pelvic ring fractures in the elderly. *EFORT*
359 *Open Rev* 2019;4(6):313-20. doi: 10.1302/2058-5241.4.180062 [published
360 Online First: 2019/07/18]
- 361 10. Handoll HHG, Cameron ID, Mak JCS, et al. Multidisciplinary rehabilitation for older
362 people with hip fractures. *Cochrane Database Syst Rev* 2009(4):77. doi:
363 10.1002/14651858.CD007125.pub2
- 364 11. Strasser DC, Uomoto JM, Smits SJ. The interdisciplinary team and polytrauma
365 rehabilitation: Prescription for partnership. *Archives of Physical Medicine and*
366 *Rehabilitation* 2008;89(1):179-81. doi: 10.1016/j.apmr.2007.06.774
- 367 12. Blaschko SD, Sanford MT, Schlomer BJ, et al. The incidence of erectile dysfunction
368 after pelvic fracture urethral injury: A systematic review and meta-analysis. *Arab*
369 *J Urol* 2015;13(1):68-74. doi: 10.1016/j.aju.2014.09.004 [published Online First:
370 2015/05/29]
- 371 13. Johnsen NV, Kaufman MR, Dmochowski RR, et al. Erectile Dysfunction Following
372 Pelvic Fracture Urethral Injury. *Sex Med Rev* 2018;6(1):114-23. doi:
373 10.1016/j.sxmr.2017.06.004 [published Online First: 2017/08/02]
- 374 14. Horiguchi A. Management of male pelvic fracture urethral injuries: Review and
375 current topics. *Int J Urol* 2019;26(6):596-607. doi: 10.1111/iju.13947
- 376 15. Shamloul R, Ghanem H. Erectile dysfunction. *Lancet* 2013;381(9861):153-65. doi:
377 10.1016/S0140-6736(12)60520-0 [published Online First: 2012/10/09]
- 378 16. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic
379 reviews and meta-analyses: the PRISMA statement. *PLoS Med*

- 1
2
3 380 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097 [published Online
4 381 First: 2009/07/22]
- 5 382 17. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic
6 383 review and meta-analysis protocols (PRISMA-P) 2015: elaboration and
7 384 explanation. *BMJ* 2015;350:g7647. doi: 10.1136/bmj.g7647 [published Online
8 385 First: 2015/01/04]
- 9 386 18. Burgess AR, Eastridge BJ, Young JW, et al. Pelvic ring disruptions: effective
10 387 classification system and treatment protocols. *J Trauma* 1990;30(7):848-56.
11 388 [published Online First: 1990/07/01]
- 12 389 19. Tile M. Acute Pelvic Fractures: I. Causation and Classification. *J Am Acad Orthop*
13 390 *Surg* 1996;4(3):143-51. doi: 10.5435/00124635-199605000-00004 [published
14 391 Online First: 1996/05/01]
- 15 392 20. Meinberg EG, Agel J, Roberts CS, et al. Fracture and Dislocation Classification
16 393 Compendium-2018. *J Orthop Trauma* 2018;32 Suppl 1:S1-S170. doi:
17 394 10.1097/BOT.0000000000001063 [published Online First: 2017/12/20]
- 18 395 21. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function
19 396 (IIEF): a multidimensional scale for assessment of erectile dysfunction. *Urology*
20 397 1997;49(6):822-30. doi: 10.1016/s0090-4295(97)00238-0 [published Online
21 398 First: 1997/06/01]
- 22 399 22. Rhoden EL, Teloken C, Sogari PR, et al. The use of the simplified International
23 400 Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence
24 401 of erectile dysfunction. *Int J Impot Res* 2002;14(4):245-50. doi:
25 402 10.1038/sj.ijir.3900859 [published Online First: 2002/08/02]
- 26 403 23. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an
27 404 abridged, 5-item version of the International Index of Erectile Function (IIEF-5)
28 405 as a diagnostic tool for erectile dysfunction. *Int J Impot Res* 1999;11(6):319-26.
29 406 doi: 10.1038/sj.ijir.3900472 [published Online First: 2000/01/19]
- 30 407 24. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for
31 408 systematic reviews. *Syst Rev* 2016;5(1):210. doi: 10.1186/s13643-016-0384-4
32 409 [published Online First: 2016/12/07]
- 33 410 25. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the
34 411 quality assessment of diagnostic accuracy studies. *Ann Intern Med*
35 412 2011;155(8):529-36. doi: 10.7326/0003-4819-155-8-201110180-00009
36 413 [published Online First: 2011/10/19]
- 37 414 26. Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors).
38 415 Cochrane Handbook for Systematic Reviews of Interventions version 6.0
39 416 (updated July 2019). *Cochrane* 2019
- 40 417 27. Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation
41 418 from the sample size, median, range and/or interquartile range. *BMC Med Res*
42 419 *Methodol* 2014;14:135. doi: 10.1186/1471-2288-14-135 [published Online First:
43 420 2014/12/20]
- 44 421 28. Luo D, Wan X, Liu J, et al. Optimally estimating the sample mean from the sample
45 422 size, median, mid-range, and/or mid-quartile range. *Stat Methods Med Res*
46 423 2018;27(6):1785-805. doi: 10.1177/0962280216669183 [published Online First:
47 424 2016/09/30]
- 48 425 29. Weir CJ, Butcher I, Assi V, et al. Dealing with missing standard deviation and mean
49 426 values in meta-analysis of continuous outcomes: a systematic review. *BMC*
50 427 *Med Res Methodol* 2018;18(1):25. doi: 10.1186/s12874-018-0483-0 [published
51 428 Online First: 2018/03/09]
- 52
53
54
55
56
57
58
59
60

- 1
2
3 429 30. R Core Team (2017). R: A language and environment for statistical computing. R
4 430 Foundation for Statistical Computing V, Austria. URL [https://www.R-](https://www.R-project.org/)
5 431 [project.org/](https://www.R-project.org/). [
6 432 31. Fanjalalaina Ralahy M, R P, riantsoa M, et al. Incidence of erectile dysfunction in
7 433 pelvic ring injuries: Study of 48 patients at the Antananarivo hospital,
8 434 Madagascar. *Orthopaedics & traumatology, surgery & research*;105(5):885-88.
9 435 32. Pastor T, Tiziani S, Kasper CD, et al. Quality of reduction correlates with clinical
10 436 outcome in pelvic ring fractures. *Injury-Int J Care Inj* 2019;50(6):1223-26. doi:
11 437 10.1016/j.injury.2019.04.015
12 438 33. Schmitz P, Ludeck S, Baumann F, et al. Patient-related quality of life after pelvic
13 439 ring fractures in elderly. *Int Orthop* 2019;43(2):261-67. doi: 10.1007/s00264-
14 440 018-4030-8 [published Online First: 2018/06/28]
15 441 34. Brouwers L, Lansink KWW, de Jongh MAC. Quality of life after pelvic ring fractures:
16 442 A cross-sectional study. *Injury* 2018;49(4):812-18. doi:
17 443 10.1016/j.injury.2018.03.012 [published Online First: 2018/03/24]
18 444 35. Montgomery B, Husmann D. Pelvic fracture urethral distraction defect (PFUDD)
19 445 with associated rectal injury: A review of acute and definitive urologic
20 446 management with long term outcomes. *J Urol* 2016;195(4):e1000.
21 447 36. Gdeh D, Haffejee M, Nel M. Frequency of Erectile Dysfunction Following Pelvic
22 448 Fracture among Patients Admitted to Two Wits Teaching Hospitals, South
23 449 Africa. *Sudan Journal of Medical Sciences* 2018;13(3):144-67.
24 450 37. King J. Impotence after fractures of the pelvis. *Journal of Bone & Joint Surgery -*
25 451 *American Volume*;57(8):1107-9.
26 452 38. Metze M, Tiemann AH, Josten C. Male sexual dysfunction after pelvic fracture.
27 453 *Journal of Trauma-Injury Infection & Critical Care*;63(2):394-401.
28 454 39. Yafi FA, Huynh LM, Ahlering T, et al. What Is a "Validated Questionnaire"? A
29 455 Critical Review of Erectile Function Assessment. *J Sex Med* 2020;17(5):849-60.
30 456 doi: 10.1016/j.jsxm.2020.02.005 [published Online First: 2020/03/09]
31 457 40. Ceylan HH, Kuyucu E, Erdem R, et al. Does pelvic injury trigger erectile dysfunction
32 458 in men? *Chinese Journal of Traumatology* 2015;18(4):229-31.
33 459 41. Duramaz A, Ilter MH, Yildiz S, et al. The relationship between injury mechanism
34 460 and sexual dysfunction in surgically treated pelvic fractures. *Eur J Trauma*
35 461 *Emerg Surg* 2020;46(4):807-16. doi: 10.1007/s00068-018-01067-0 [published
36 462 Online First: 2019/01/09]
37 463 42. Harwood PJ, Grotz M, Eardley I, et al. Erectile dysfunction after fracture of the
38 464 pelvis. *J Bone Joint Surg Br* 2005;87(3):281-90. doi: 10.1302/0301-
39 465 620x.87b3.15662 [published Online First: 2005/03/19]
40 466 43. Armenakas NA, McAninch JW, Lue TF, et al. Posttraumatic impotence: magnetic
41 467 resonance imaging and duplex ultrasound in diagnosis and management. *J Urol*
42 468 1993;149(5 Pt 2):1272-5. doi: 10.1016/s0022-5347(17)36365-6 [published
43 469 Online First: 1993/05/01]
44 470 44. Robinson LQ, Woodcock JP, Stephenson TP. Results of investigation of impotence
45 471 in patients with overt or probable neuropathy. *Br J Urol* 1987;60(6):583-7. doi:
46 472 10.1111/j.1464-410x.1987.tb05046.x [published Online First: 1987/12/01]
47 473 45. Ellison M, Timberlake GA, Kerstein MD. Impotence following pelvic fracture.
48 474 *Journal of Trauma-Injury Infection & Critical Care*;28(5):695-6.
49 475 46. Shenfeld OZ, Kiselgorf D, Gofrit ON, et al. The incidence and causes of erectile
50 476 dysfunction after pelvic fractures associated with posterior urethral disruption. *J*
51 477 *Urol*;169(6):2173-6.
52
53
54
55
56
57
58
59
60

- 1
2
3 478 47. Munarriz RM, Yan QR, A ZN, et al. Blunt trauma: the pathophysiology of
4 479 hemodynamic injury leading to erectile dysfunction. *J Urol* 1995;153(6):1831-
5 480 40. doi: 10.1016/s0022-5347(01)67324-5 [published Online First: 1995/06/01]
6 481 48. Mark SD, Keane TE, emark RM, et al. Impotence following pelvic fracture urethral
7 482 injury: incidence, aetiology and management. *British Journal of*
8 483 *Urology*;75(1):62-4.
9 484 49. Blaschko SD, Sanford MT, Schlomer BJ, et al. The incidence of erectile dysfunction
10 485 after pelvic fracture urethral injury: A systematic review and meta-analysis. *Arab*
11 486 *Journal of Urology Print*;13(1):68-74.
12 487 50. Anger JT, Sherman ND, Dielubanza E, et al. Erectile function after posterior
13 488 urethroplasty for pelvic fracture-urethral distraction defect injuries. *BJU*
14 489 *Int*;104(8):1126-9.
15 490 51. Johnsen NV, Kaufman MR, Dmochowski RR, et al. Erectile Dysfunction Following
16 491 Pelvic Fracture Urethral Injury. *Sexual Medicine Reviews*;6(1):114-23.
17 492 52. Barratt RC, Bernard J, Mundy AR, et al. Pelvic fracture urethral injury in males-
18 493 mechanisms of injury, management options and outcomes. *Translational*
19 494 *Andrology & Urology*;7:S29-S62.
20 495 53. Light A, Gupta T, Dadabhoy M, et al. Outcomes Following Primary Realignment
21 496 Versus Suprapubic Cystostomy with Delayed Urethroplasty for Pelvic Fracture-
22 497 Associated Posterior Urethral Injury: A Systematic Review with Meta-Analysis.
23 498 *Current Urology*;13(3):113-24.
24 499 54. Scarberry K, Bonomo J, Gomez RG. Delayed Posterior Urethroplasty Following
25 500 Pelvic Fracture Urethral Injury: Do We Have to Wait 3 Months?
26 501 *Urology*;116:193-97.
27 502 55. Zou Q, Zhou S, Zhang K, et al. The Immediate Management of Pelvic Fracture
28 503 Urethral Injury-Endoscopic Realignment or Cystostomy? *J Urol*;198(4):869-74.
29 504 56. Rey VM, Fernandez C, Zanabili A, et al. Endovascular Repair of Iliac Vein
30 505 Laceration Associated with Complex Pelvic Fracture. *Ann Vasc Surg* 2019;54:4.
31 506 doi: 10.1016/j.avsg.2018.06.020
32 507 57. Baca V, Bacova T, Grill R, et al. Pudendal nerve in pelvic bone fractures. *Injury*
33 508 2013;44(7):952-56. doi: 10.1016/j.injury.2012.12.004 [published Online First:
34 509 2013/02/07]
35 510 58. Wright JL, Nathens AB, Rivara FP, et al. Specific fracture configurations predict
36 511 sexual and excretory dysfunction in men and women 1 year after pelvic fracture.
37 512 *J Urol*;176(4):1540-5; discussion 45.
38 513 59. Wright JL, Wessells HB, Nathens AB, et al. Sexual and excretory dysfunction one
39 514 year after pelvic fracture. *J Urol*;173(4):91-91.
40 515 60. Harvey-Kelly KF, Kanakaris NK, Obakponovwe O, et al. Quality of life and sexual
41 516 function after traumatic pelvic fracture. *Journal of Orthopaedic*
42 517 *Trauma*;28(1):28-35.
43 518 61. Harvey-Kelly KF, Kanakaris NK, Eardley I, et al. Sexual function impairment after
44 519 high energy pelvic fractures: evidence today. *J Urol*;185(6):2027-34.
45 520 62. Delle Rose A, Stomaci N, Pironti M, et al. Impotence due to pelvic trauma:
46 521 Treatment with papaverine and PGE1. *Acta Urologica Italica* 1992;6:27-28.
47 522 63. Shenfeld OZ, Gofrit ON, Gdor Y, et al. The role of sildenafil in the treatment of
48 523 erectile dysfunction in patients with pelvic fracture urethral disruption. *J*
49 524 *Urol*;172(6):2350-2.
50 525 64. Ventimiglia E, Capogrosso P, Montorsi F, et al. The safety of phosphodiesterase
51 526 type 5 inhibitors for erectile dysfunction. *Expert Opin Drug Saf* 2016;15(2):141-
52 527 52. doi: 10.1517/14740338.2016.1131818 [published Online First: 2016/01/12]

- 1
2
3 528 65. Goldstein I, Tseng LJ, Creanga D, et al. Efficacy and Safety of Sildenafil by Age in
4 529 Men With Erectile Dysfunction. *J Sex Med* 2016;13(5):852-9. doi:
5 530 10.1016/j.jsxm.2016.02.166 [published Online First: 2016/04/27]
6 531 66. Liao X, Qiu S, Bao Y, et al. Comparative efficacy and safety of phosphodiesterase
7 532 type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network
8 533 meta-analysis of randomized controlled trials. *World J Urol* 2019;37(6):1061-74.
9 534 doi: 10.1007/s00345-018-2583-1 [published Online First: 2018/12/14]
10 535 67. Gong B, Ma M, Xie W, et al. Direct comparison of tadalafil with sildenafil for the
11 536 treatment of erectile dysfunction: a systematic review and meta-analysis. *Int*
12 537 *Urol Nephrol* 2017;49(10):1731-40. doi: 10.1007/s11255-017-1644-5
13 538 [published Online First: 2017/07/26]
14 539 68. Liu C, Lopez DS, Chen M, et al. Penile Rehabilitation Therapy Following Radical
15 540 Prostatectomy: A Meta-Analysis. *J Sex Med* 2017;14(12):1496-503. doi:
16 541 10.1016/j.jsxm.2017.09.020 [published Online First: 2017/11/11]
17 542 69. Philippou YA, Jung JH, Steggall MJ, et al. Penile rehabilitation for
18 543 postprostatectomy erectile dysfunction. *Cochrane Database Syst Rev*
19 544 2018;10:CD012414. doi: 10.1002/14651858.CD012414.pub2 [published Online
20 545 First: 2018/10/24]
21 546 70. Qiu S, Tang Z, Deng L, et al. Comparisons of regular and on-demand regimen of
22 547 PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for
23 548 Prostate Cancer. *Sci Rep* 2016;6:32853. doi: 10.1038/srep32853 [published
24 549 Online First: 2016/09/10]
25 550 71. Nieto-Esquivel A, Delgado-Balderas R, Robles-Torres JI, et al. [Use of tadalafil in
26 551 the rehabilitation of patients with a history of posterior urethral injury in the
27 552 context of pelvic fracture]. *Revista Internacional de Andrologia*;16(1):15-19.
28 553 72. Fu Q, Sun X, Tang C, et al. An assessment of the efficacy and safety of sildenafil
29 554 administered to patients with erectile dysfunction referred for posterior
30 555 urethroplasty: a single-center experience. *J Sex Med*;9(1):282-7.
31 556 73. Peng J, Zhang Z, Gao B, et al. Effect of daily sildenafil on patients with absent
32 557 nocturnal erections due to pelvic fracture urethral disruption: A singlecenter
33 558 experience. *J Sex Med* 2017;14(1):S25.
34 559 74. Qiang F, Xianjun S, Chenye T, et al. The efficacy and safety of sildenafil on
35 560 treatment of patients with erectile dysfunction referred for posterior
36 561 urethroplasty: A single center experience. *Chinese Journal of Andrology*
37 562 2011;25(8):27-31.
38 563 75. Wang CJ, Lu YM, Li CC, et al. Low-intensity shock wave therapy ameliorates
39 564 erectile dysfunction in men with pelvic fractures associated with urethral injury.
40 565 *Int J Impot Res*;31(3):218-22.
41 566 76. Zhang DL, Chen Z, Wang FX, et al. Adding a vacuum erection device to regular
42 567 use of Tadalafil improves penile rehabilitation after posterior urethroplasty.
43 568 *Asian J Androl*;21(6):582-86.
44 569 77. Song L, Fu Q. The role of vacuum erection devices in penile rehabilitation after
45 570 posterior urethral anastomotic urethroplasty:A pilot study. *J Urol*
46 571 2017;197(4):e1224-e25.
47 572 78. Hellstrom WJ, Montague DK, Moncada I, et al. Implants, mechanical devices, and
48 573 vascular surgery for erectile dysfunction. *J Sex Med* 2010;7(1 Pt 2):501-23. doi:
49 574 10.1111/j.1743-6109.2009.01626.x [published Online First: 2010/01/23]
50 575
51
52
53
54
55
56
57
58
59
60

576 **Figures Legend**

577

578 **Figure 1**

579 PRISMA flow diagram of study selection

580 **Figure 2**

581 Weighted forest plot displaying the proportion of patients developing ED according to PRF
582 classification.

583 *Abbreviations: ABC = Tile A, B and C fractures; APC = anteroposterior compression, LC =*
584 *lateral compression and VS = vertical shear according Young & Burgess; PFUI = pelvic*
585 *fracture urethral injury.*

586 **Figure 3**

587 Forest plot displaying the treatment effect as mean change score between IIEF-5 scores
588 before and after penile rehabilitation treatment with PDE-5-I.

589 *Abbreviations: PFUI = pelvic fracture urethral injury.*

590 **Figure 4**

591 Domains in risk of bias of all included studies according to QUADAS-2 tool. Traffic light plot
592 (A) and weighted summary plot (B).

Table 1: Included articles

Author	Year	Country	Study Design	n	mean age	Inclusion	DOI
Nieto	2017	Mexico	Retrospective Cohort Study	8	32.5	Treatment effect PDE-5-I	10.1136/j.androl.2017.02.004
Peng	2014	China	Retrospective Cohort Study	31	33.1	Treatment effect PDE-5-I	10.1111/and.12548
Peng	2015	China	NFS	28	34	Treatment effect PDE-5-I	10.1116/j.urology.2014.08.006
Chung	2018	USA	Retrospective Cohort Study	29	52	Incidence of ED after PRF	10.1116/j.urology.2018.01.035
Duramaz	2019	Turkey	Retrospective Cohort Study	52	35	Incidence of ED after PRF	10.1107/s00068-018-01067-0
Fanjalaalaina	2019	Madagascar	Retrospective Cohort Study	42	39.6	Incidence of ED after PRF	10.1116/j.otsr.2019.01.026
Malavaud	2000	France	Retrospective Cohort Study	37	37.8	Incidence of ED after PRF	10.1116/s0090-4295(00)00492-1

n = number of patients


PMID = PubMed ID

PDE-5-I = Phosphodiesterase 5 inhibitor

PRF = Pelvic ring fracture

ED = Erectile dysfunction


Figure 1: PRISMA flow diagram of study selection



BMJ Open: first published as 10.1136/bmjopen-2020-015117 on 28 May 2021. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59


Injury	Author	Year	Country	N	Months of Follow-up	Proportion [95% CI]
ABC	Malavaud	2000	France	37	26.8	0.30 [0.17, 0.46]
A	Fanjalalaina	2019	Madagascar	29	12.5	0.24 [0.12, 0.43]
B	Fanjalalaina	2019	Madagascar	8	12.5	0.62 [0.28, 0.87]
C	Fanjalalaina	2019	Madagascar	5	12.5	0.80 [0.31, 0.97]
APC	Duramaz	2019	Turkey	12	27	0.42 [0.18, 0.69]
LC	Duramaz	2019	Turkey	20	27	0.02 [0.00, 0.29]
VS	Duramaz	2019	Turkey	20	27	0.40 [0.21, 0.62]
no_PFUI	Chung	2018	USA	21	56.4	0.38 [0.20, 0.60]
PFUI	Chung	2018	USA	29	46.8	0.59 [0.40, 0.75]
RE Model	(Q = 18.01, p = 0.021; I ² = 44.2%, H ² = 1.8)			181		0.37 [0.26, 0.50]



BMJ Open: first published as 10.1136/bmjopen-2020-025117 on 28 May 2021. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Author, Year	Injury	Country	N	Treatment	Months of Treatment	IIEF-5 post-pre	Change Score [95% CI]
Nieto, 2017	PFUI	Mexico	8	Tadalafil, 5mg	3		10.75 [8.04, 13.46]
Peng, 2014	PFUI	China	31	Sildenafil, 50mg	3		4.00 [3.01, 4.99]
Peng, 2015	PFUI	China	28	Sildenafil, 50mg	3		5.22 [3.25, 7.19]

RE Model (Q = 21.14, p < 0.0001; I² = 93.0%, H² = 14.3) 67 6.50 [2.54, 10.46]




A

Study	Risk of bias domains				
	D1	D2	D3	D4	Overall
Chung et al. (2018)	X	+	?	X	X
Duramaz et al. (2019)	+	+	X	X	X
Fanjalaalaina et al. (2019)	+	+	X	+	X
Malavaud et al. (2000)	+	+	X	X	X
Nieto et al. (2017)	X	+	X	X	X
Peng et al. (2014)	X	+	?	X	X
Peng et al. (2015)	X	+	?	X	X

Domains:
 D1: Patient selection
 D2: IIEF-5 questionnaire
 D3: Fracture classification
 D4: Flow & timing

Judgement
 X High
 + Low
 ? No information

B



BMJ Open: first published as 10.1136/bmjopen-2020-045117 on 28 May 2021. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

1 Search Strategy

2 COCHRANE

3 ((pelvic OR pelvis OR acetabular OR acetabulum) NEAR/3 (fracture* OR trauma*)):ti,ab,kw
4 AND erectile NEAR/3 (dysfunction OR function OR process OR failure OR capacity OR
5 disorder* OR problem*)):ti,ab,kw OR (sexual NEAR/3 dysfunction):ti,ab,kw OR (erection OR
6 impotence OR iief):ti,ab,kw

8 EMBASE

9 ('pelvis fracture'/exp OR (((pelvic OR pelvis OR acetabular OR acetabulum) NEAR/3 (fracture*
10 OR trauma*)):ti,ab)) NOT ([conference abstract]/lim AND [1974-2014]/py)
11 AND 'erectile dysfunction'/exp OR 'penis erection'/exp OR 'international index of erectile
12 function'/exp OR ((erectile NEAR/3 (dysfunction OR function OR process OR failure OR
13 capacity OR disorder* OR problem*)):ti,ab) OR ((sexual NEAR/3 dysfunction):ti,ab) OR
14 erection:ti,ab OR impotence:ti,ab OR 'iief':ti,ab

16 MEDLINE

17 (exp Pelvic Bones/ and Fractures, Bone/) or exp Pelvic Bones/in or ((pelvic or pelvis or
18 acetabular or acetabulum) adj3 (fracture* or trauma*)):ti,ab. AND exp Erectile Dysfunction/ or
19 Penile Erection/ or (erectile adj3 (dysfunction or function or process or failure or capacity or
20 disorder* or problem*)):ti,ab. or (sexual adj3 dysfunction).ti,ab. or (erection or impotence or
21 'iief').ti,ab.

23 SCOPUS

24 (TITLE-ABS-KEY(((pelvic OR pelvis OR acetabular OR acetabulum) W/3 (fracture* OR
25 trauma*))) AND (TITLE-ABS-KEY(erectile W/3 (dysfunction OR function OR process OR
26 failure OR capacity OR disorder* OR problem*))) OR TITLE-ABS-KEY(sexual W/3 dysfunction)
27 OR TITLE-ABS-KEY(erection OR impotence OR iief))

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

29 WEB OF SCIENCE

30 TS=((pelvic OR pelvis OR acetabular OR acetabulum) NEAR/3 (fracture* OR trauma*)) AND

31 TS=(erectile NEAR/3 (dysfunction OR function OR process OR failure OR capacity OR

32 disorder* OR problem*)) OR TS=(sexual NEAR/3 dysfunction) OR TS=(erection OR impotence

33 OR iief)

34

For peer review only

BMJ Open

Erectile Dysfunction and Penile Rehabilitation after Pelvic Fracture – a Systematic Review and Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-045117.R1
Article Type:	Original research
Date Submitted by the Author:	22-Apr-2021
Complete List of Authors:	Schmid, Florian; University Hospital Zurich, Urology; University of Zurich Faculty of Medicine, Held, Ulrike; University of Zurich, Epidemiology, Biostatistics and Prevention Institute Eberli, Daniel; University Hospital Zurich, Urology; University of Zurich Faculty of Medicine, Pape, Hans-Christoph; University Hospital Zurich, Trauma; University of Zurich Faculty of Medicine, Halvachizadeh, Sascha; University Hospital Zurich, Trauma; University of Zurich Faculty of Medicine,
Primary Subject Heading:	Surgery
Secondary Subject Heading:	Urology, Sexual health
Keywords:	ORTHOPAEDIC & TRAUMA SURGERY, Trauma management < ORTHOPAEDIC & TRAUMA SURGERY, UROLOGY, Male infertility < UROLOGY, Sexual dysfunction < UROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Erectile Dysfunction and Penile Rehabilitation after Pelvic Fracture – a Systematic Review and Meta- Analysis

Systematic Review

Florian A. Schmid ¹, Ulrike Held ², Daniel Eberli ¹, Hans-Christoph Pape ³,
Sascha Halvachizadeh ³

¹ University Hospital Zurich, Department of Urology, University of Zurich, Zurich, Switzerland

² University of Zurich, Department of Biostatistics at Epidemiology, Biostatistics and
Prevention Institute, Zurich, Switzerland

³ University Hospital Zurich, Department of Trauma, University of Zurich, Zurich, Switzerland

Corresponding author:

Sascha Halvachizadeh, MD

Department of Trauma

University Hospital Zurich

Rämistrasse 100

8091 Zurich, Switzerland

Tel: +41 44 255 11 11

Email: sascha.halvachizadeh@usz.ch

Abstract word count: 283

Manuscript word count: 3358

Abstract

Objective

To investigate the rate of erectile dysfunction (ED) after pelvic ring fracture (PRF).

Design

Systematic review, and meta-analysis.

Methods

A systematic literature search of the Cochrane, EMBASE, MEDLINE, Scopus and Web of Science Library databases was conducted in January 2020. Included were original studies performed on humans assessing ED after PRF according the 5-item International Index of Erectile Function (IIEF-5) questionnaire and fracture classification following Young & Burgess, Tile or AO/OTA (Arbeitsgemeinschaft für Osteosynthesefragen / Orthopedic Trauma Association). Further, interventional cohort studies assessing the effect of penile rehabilitation therapy with phosphodiesterase-5-inhibitors (PDE-5-I) on IIEF-5 scores compared before and after treatment were included. Results were presented as forest plots of proportions of patients with ED after PRF or mean changes on IIEF-5 questionnaires before and after penile rehabilitation. Studies not included in the quantitative analysis were narratively summarized. Risk of bias assessment was conducted using the revised tool for the Quality Assessment on Diagnostic Accuracy studies (QUADAS-2).

Results

The systematic literature search retrieved 617 articles. Seven articles were included in the qualitative analysis and the meta-analysis. Pooled proportions revealed 37% of patients with ED after suffering any form of PRF (result on probability scale $pr = 0.37$, 95% CI: 0.26 to 0.50). Patients after 3 months of penile rehabilitation therapy reported a higher IIEF-5 score than before (change score [CS] = 6.5 points, 95% CI: 2.54 to 10.46, p -value = 0.0013).

Conclusion

1
2
3 Despite some heterogeneity and limited high quality research, this study concludes that
4 patients suffering from any type of PRF have an increased risk of developing ED. Oral intake
5 of PDE-5-I for the purpose of penile rehabilitation therapy increases IIEF-5 scores and may
6
7
8
9
10 relevantly influence Quality of Life (QoL) in these patients.

11 **Trial registration number**

12
13
14 PROSPERO ID: CRD42020169699

15 **Strengths and limitations**

- 16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Despite strict definition of PRF and ED, there is still an inevitable variability due to the heterogeneous methodological nature of available studies and study populations from different centers worldwide.
 - Resulting from the lack of standardization, a broad variety of classifications for PRF and different definitions and questionnaires for the evaluation of ED were used.
 - Included studies provide a certain risk of bias.
 - The included results were consistent across studies.

Introduction

Pelvic ring fractures (PRF) result from high-energy injuries and are associated with devastating acute and chronic complications as severe and life-threatening hemorrhage or chronic pain and impaired ambulation¹⁻⁵. The initial treatment of PRF is guided by the fracture morphology, pathophysiologic reaction of the organism to the trauma and concomitant injuries⁶⁻⁹. After initial hemodynamic stabilization and fixation of the PRF, an interdisciplinary team-approach aims to improve long-term outcomes and to reduce complications^{10 11}. In male patients suffering PRF, erectile dysfunction (ED) is one of the main long-term complications. ED ranks among the adverse effects after PRF that severely impair the quality of life (QoL) in these patients, especially when urogenital damage is involved¹²⁻¹⁴. The treatment of ED depends on the underlying pathogenesis and on patient-specific factors – it ranges from psychological behavior therapy and pharmacological support until surgical interventions¹⁵. The incidence of ED after PRF varies across the published literature due to a lack of epidemiologic studies investigating this subject, indicating a high number of unreported cases. It further remains unclear what the consequences of ED after PRF in the young male population is and whether patients with PRF benefit from early pharmacological penile rehabilitation therapy with phosphodiesterase-5-inhibitors (PDE-5-I). Therefore, this meta-analysis aims to answer the following questions: A) Is the incidence of ED associated with the severity of PRF? B) What is the treatment effect of penile rehabilitation after PRF with the help of PDE-5-I? We hypothesize, that the rate of ED is associated with the increasing severity of PRFs and that pharmacological penile rehabilitation improves blood circulation in the pelvic organ region and therefore reduces the chances of persistent ED.

Methods

This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines^{16 17}. It was recorded on PROSPERO, the prospective register of systematic reviews, under the registration ID: CRD42020169699.

Search strategy and definitions

A scientific librarian and information expert, specialized in medical research, conducted a systematic literature search of the Cochrane, EMBASE, MEDLINE, Scopus and Web of Science Library databases in January 2020. PRF are classified following Young and Burgess¹⁸, Tile¹⁹ or the AO/OTA classification²⁰. ED was evaluated based on the 5-item International Index of Erectile Function (IIEF-5) questionnaire^{21 22}. Presence of ED was defined as a score between 5 and 21 (severe-mild ED) according to results on IIEF-5 questionnaires. Categorization according to the achieved IIEF-5 score leads to the following subgrouping: "Severe" (5-7 points), "moderate" (8-11 points), "mild to moderate" (12-16 points), "mild" (17-21 points) and "no" (22-25 points) ED²³. The term "penile rehabilitation" refers to the treatment of ED with PDE-5-I. Penile rehabilitation is a urological concept to enhance ED in patients after nerve-sparing radical prostatectomy due to prostate cancer. The idea of this treatment is to enhance blood circulation in the postoperative period (3-6 months) after the intervention in order to ameliorate neurovascular regeneration and to avoid cavernous fibrosis. Although penile rehabilitation has been subject to some debate, this concept might be also helpful in young male patients after trauma to the pelvis. PRFs frequently lead to damage in the neurovascular structures of the pelvis. As a consequence, male patients may experience ED and therefore a severely reduced quality of life.

Inclusion / exclusion criteria

1
2
3 Inclusion criteria were original studies performed on humans assessing ED after PRF written
4 in French, Spanish, Italian, German and English language. No specific time limits were used.
5
6 To increase comparability, we only included articles that assessed ED based on IIEF-5 and
7 classified the severity of PRF accordingly (see above). We included interventional cohort
8 studies assessing the effect of PDE-5-I on ED after PRF with the reported change of the IIEF-5
9 scores prior and after PDE-5-I treatment as main outcome parameter. Articles assessing
10 secondary ED after treatment of urethral injuries were excluded. Further, articles without full-
11 text availability were excluded. Case reports, case series, narrative reviews, expert opinions,
12 editorials, book chapters, conference abstracts, letters, commentaries, correspondences, in
13 vitro and animal experiments were completely excluded from the systematic review. The full
14 search string is shown in the *Supplementary*.

27 **Data management**

28
29
30 The export of de-duplicated publications from all sources were saved in an EndNote library.
31 Two authors (FAS and SH) received the same library and independently screened and
32 assorted all articles within the publicly available web-tool Rayyan ²⁴.

38 **Study selection**

39
40
41 According to the PRISMA flow diagram, steps of screening were performed as follows ¹⁶: 1.)
42 title and abstract screening, 2.) full text screening, 3.) extraction and storage of data, 4.)
43 qualitative and quantitative evidence synthesis. After title and abstract screening, full texts
44 were obtained for formal inclusion or exclusion into our systematic review. Full text analysis
45 was performed independently by two authors (FAS and SH). Discrepancies were resolved by
46 consensus or, if necessary, until consensus was reached. Studies that did not provide the type
47 of PRF and the subsequent proportion of patients with ED, as well as no baseline scores of
48 IIEF-5 questionnaires (before PDE-5-I therapy) for the evaluation of penile rehabilitation, were
49 not included in the quantitative analysis. However, some of these studies were summarized in
50 a narrative way.
51
52
53
54
55
56
57
58
59
60

Data extraction

The following data was extracted from published articles: (i) general study information: author, year, country, study design (i.e. prospective or retrospective); (ii) patient characteristics: sample size, age, type of pelvic injury (category), follow-up time (months); (iii) outcome: rate of patients with ED (proportion), mean or median IIEF-5 score (absolute values) either after trauma and follow-up or before and after treatment, IIEF-5 category (categorical values); associated injuries (iv): urogenital injuries (proportion) or urethral injury (proportion), other injury sites (amount); treatment (v): medication (type of PDE-5-I), dosage (mg) and treatment duration (months).

The data was extracted independently and in duplicate by two authors (FAS and SH) on separate copies of an Excel spreadsheet. These were compared and discrepancies were resolved by consensus.

Risk of bias

Risk of bias assessment was conducted using the revised tool for the Quality Assessment on Diagnostic Accuracy studies (QUADAS-2)²⁵. Each study was assessed for risk of bias through four key domains: patient selection, usage of standardized IIEF-5 questionnaires, grouping into internationally accepted pelvic fracture classifications and flow & timing. For each domain, the two authors (FAS and SH) independently assigned a rating of low, high or unclear risk of bias. Again, discrepancies were resolved through discussion or until consensus was reached.

Statistical analysis

Descriptive statistics on study level were reported as means and proportions. For evidence synthesis for continuous outcomes, means with standard deviations (SD) were used for

1
2
3 pooling in a random effects model. If studies reported means with standard errors (SE), the
4
5
6 SD was computed using the formula provided by the Cochrane Collaboration: $SD = SE * \sqrt{N}$
7
8
9 ²⁶. For studies which reported values as median with range or interquartile range (IQR), we
10
11 estimated the mean and SD according to the formulas by Wan et al. ²⁷. To confirm the reliability
12
13 of these estimations, we performed them in duplicate using the formulas by Luo et al. ²⁸, and
14
15 compared the results of the two methods. Both methods have in general shown good reliability
16
17 for these estimations, even in presence of deviation from the normal distribution ²⁹. Evidence
18
19 synthesis for binary outcomes was done by dividing reported numbers of patients with the
20
21 condition over total number of patients in each study, and these proportions were used for
22
23 pooling in a random effects logistic regression model. The random effects model computes
24
25 exact 95% confidence intervals (CI) based on the binomial distribution for the overall effect.
26
27 Results were presented as forest plots of mean changes of IIEF-5 questionnaires before and
28
29 after penile rehabilitation, or proportions of patients with ED including 95% CI. In one forest
30
31 plot, studies were ordered by subtypes of pelvic ring fractures. To quantify heterogeneity, the
32
33 Q-test (total between-study variance), I^2 - (proportion of total variation) and H^2 -statistic (ratio of
34
35 total amount of variability and amount of sampling variance) was calculated for all meta-
36
37 analyses . All statistical analyses were performed using R (version 3.4.2) ³⁰.
38
39
40
41
42
43
44

45 Patient and Public Involvement

46
47
48 No patient involved
49
50
51
52
53
54
55
56
57
58
59
60

Results

Study selection and characteristics

According to the systematic literature research and after removal of duplicates, 617 articles were found. The initial screening process for title and abstract excluded 556 articles. The full-text analysis of the remaining 61 articles led to the exclusion of further 54 articles. We included four articles assessing the incidence of ED after PRF based on IIEF-5 and three articles investigating the treatment effect of PDE-5-I on ED after PRF (*Figure 1*). Articles included for qualitative and quantitative analysis were published between the years 2000 and 2019 and were all retrospective cohort studies (*Table 1*).

Incidence of ED after PRF

The analysis for the incidence of ED after PRF included 181 male patients with mean age 42 years. Out of these, 65 patients (35.9%) reported ED based on IIEF-5 score of ≤ 21 points.

The mean follow-up was 24.01 ± 10.91 months. The overall mean IIEF-5 score was 20.01 ± 2.01 points. The rate of ED after anterior-posterior compression (APC) fracture or Type A fractures was 29.27%. The rate of ED after lateral compression (LC) or Type B PRF was 17.86%. After vertical shear (VS) or Type C PRF 48% of patients suffered from ED. PRF with associated pelvic fracture urethral injury (PFUI) led to a higher percentage of ED than PRF without PFUI (58.6 % vs. 38.1%). Pooling the proportions with the random effects model resulted in 37% of patients with ED after suffering any form of PRF (result on probability scale

pr = 0.37, 95% CI: 0.26 to 0.50). As a measure of heterogeneity, the percentage of variability (I^2) was moderate with 44.2% (p-value = 0.021).

Elevated probabilities for the development of ED after PRF was described in Tile fractures type B and C (pr = 0.62; 95% CI: 0.28 to 0.87 and pr = 0.80; 95% CI: 0.31 to 0.97, respectively) as well as with injuries associated with PFUI (pr = 0.59; 95% CI: 0.40 to 0.75). Duramaz et al. reported higher proportions of ED in patients with APC and VS (pr = 0.42; 95% CI: 0.18 to 0.69 and pr = 0.40; 95% CI: 0.21 to 0.62, respectively) compared to LC fractures (pr = 0.02; 95% CI: 0.00 to 0.29) according Young & Burgess. Fanjalalaina and colleagues reported the highest proportion of ED with 80% of patients affected after PRF Tile C (pr = 0.80; 95% CI: 0.31 to 0.97). The lowest proportion of ED was demonstrated by Duramaz et al. in LC fractures with 0% of patients developing ED after a follow up of 27 months (pr = 0.02; 95% CI: 0.00 to 0.29). Further, the type A fractures presented by Fanjalalaina et al. and the overall chances to develop ED in a combined group of A, B and C fractures from Malavaud reported all lower probabilities than the studies of comparison (pr = 0.24; 95% CI: 0.12 to 0.43 and OR = 0.30; 95% CI: 0.17 to 0.46, respectively). For overall results, please see forest plot in *Figure 2*.

Effect of penile rehabilitation in patients with PRF

Three studies with cumulative 67 patients investigated the effect of penile rehabilitation using PDE-5-I for the treatment of ED after PRF with concomitant PFUI. The mean age of patients across studies was 33 years. Either Sildenafil (50 mg) or Tadalafil (5 mg) were used for a treatment duration of three months. The mean IIEF-score after PRF and before treatment was 6.69 ± 1.16 points and increased to 13.3 ± 4.5 points after PDE-5-I treatment. There was strong evidence that the IIEF-5 score in patients after penile rehabilitation therapy was higher than the IIEF-5 score before treatment (change score [CS] = 6.5 points increase, 95% CI: 2.54 to 10.46, p-value = 0.0013). The largest difference in IIEF-5 scores before and after 3 months of

1
2
3 Tadalafil treatment (5 mg) was reported by Nieto et al. (CS = 10.75, 95% CI: 8.04 to 13.46).
4
5 Peng and colleagues published in 2014 the smallest effect of penile rehabilitation therapy after
6
7 3 months of Sildenafil (50 mg) with a statistically higher IIEF-score, comparing before and after
8
9 treatment (CS = 4.00, 95% CI: 3.01 to 4.99). A considerable heterogeneity was observed
10
11 between the studies in this meta-analysis, justifying the use of a random effects model ($I^2 =$
12
13 93%, $p < 0.0001$). For summarized results, please see forest plot in *Figure 3*.
14
15
16
17

18 **Study quality**

19
20
21 The assessment of study quality is depicted in *Figure 4*. The overall quality of the included
22
23 studies was low due to a rather high risk of bias. We found selection bias to be a concern for
24
25 more than half of the included studies. This was due to studies not following consecutive
26
27 recruitment, no or partial definition of inclusion and exclusion criteria as well as time and/or
28
29 place of recruitment. Either no or only sparse information was available on the different types
30
31 of fractures that were subdivided into groups of internationally accepted classifications. Finally
32
33 yet importantly, flow & timing of the study was associated with a high risk of bias in almost all
34
35 cases, except for Fanjalalaina and colleagues ³¹.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

PRF resulting from high-energy trauma is associated with increased mortality³, impaired QoL³²⁻³⁴ and concomitant injuries of pelvic organs³⁵. Amongst other adverse effects, ED is an underestimated functional complication in male patients after PRF³⁶. The aim of this article was to assess the rate of ED after PRF and the effect of pharmacological penile rehabilitation with PDE-5-I on assessed, standardized IIEF-5 questionnaires. The following three points can be regarded as quintessence of this systematic review and the underlying meta-analysis: A) Males after PRF have a significant risk (37%) of developing any form of ED according to IIEF-5 scores, independent of injury severity. B) Pharmacological penile rehabilitation with PDE-5-I improves the individual IIEF-5 score by 6.5 points after a consecutive treatment of 3 months following injury in a male cohort with PRF and PFUI.

Rate of ED after PRF

The rate of ED after PRF is subject of substantial research activities. In one of the first published manuscripts dealing with this topic in 1975, King et al. reviewed 90 patients and noted an incidence of 5-42% of ED after pelvic trauma, already claiming that ED was more commonly associated with concomitant urethral injury³⁷. In 2007, Metze and colleagues investigated the rate of ED after PRF in 77 men utilizing a the long version of the IIEF questionnaire for evaluation: They reported 61% of patients with limitations in sexual function, 19% with persistent impairment and an increased risk of persistence with associated posterior ring disruptions (Tile C)³⁸. The IIEF is known to be a simple questionnaire that meets established criteria, is consistent and reliable regarding test-retest reproducibility. Its' validity to evaluate improvement of EF after ED treatment is further justified³⁹. Another study noted the rate of moderate and severe ED based on the IIEF-5 score to be 46.1%, increasing in line with the complexity of the fractures (Tile B and C), whereas mild and moderate forms of ED were present in 53.9% of patients affected from type A fractures⁴⁰. A recent publication concluded, similar to our observed results, that APC and VS fractures according to Young &

1
2
3 Burgess are more associated with ED in men and sexual dysfunction in both sexes, than LC
4 fractures ⁴¹. In a review article from Harwood and colleagues, the rate of ED after pelvic
5 fractures without PFUI ranges from 5 to 24% and from 9 to 72% with PFUI ⁴². They discussed
6 the broad variance of assessment tools for ED as well as concomitant injuries as relevant
7 reasons for the broad variability of the gathered data ⁴². Several studies investigated the
8 pathogenesis of ED following pelvic fractures, identifying vasculogenic ⁴³⁻⁴⁷, neurogenic ^{43-46 48}
9 and psychogenic ^{44 47} etiologies. One of the most commonly investigated risk factor for
10 developing ED following PRF is the presence and severity of urethral injuries as collateral
11 damage ^{13 46 49-51}. However, the management and the relevance of early vs. delayed surgical
12 or conservative treatment approaches after PFUI is still controversially discussed ⁵²⁻⁵⁵.
13 Excluding PFUI, the present study concludes an incidence of ED based on standardized IIEF-5
14 questionnaires of 41.5% ranging from 29.7 to 71.4%, whereas the broad variance of incidence
15 is mostly depending on injury severity. According to our meta-analysis, there is a visible trend
16 for an increased rate of ED among higher classifications of PRF injuries. The severity of PRFs
17 are associated with concomitant injuries such as vascular ⁵⁶, nerve ⁵⁷ as well as abdominal
18 and urogenital organ damage ³⁵. Wright and colleagues identified that patients with sacroiliac
19 fractures to have at least a four times higher risk for sexual and excretory dysfunction ⁵⁸.
20 Further, it has been demonstrated, that patients suffer from a decreased QoL after more
21 severe forms of PRFs ^{33 59 60}. All these risk factors, including higher trauma energy, are
22 therefore associated with the development of persistent ED ^{42 61}.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **Treatment of ED after PRF**

51 Strategies to treat ED as a consequence of PRF include pharmacological, mechanical and
52 invasive treatment approaches. Initial attempts in Italy used Papaverine and Prostaglandin E1
53 as vasodilative, intracavernous injections ⁶². In 2004, Shenfield et al. treated patients with
54 ED after PFUI with 100mg oral Sildenafil (PDE-5-I) on demand for 3-6 months. Forty-seven
55 percent responded favorably to treatment, of which one third reported resumption of normal
56
57
58
59
60

1
2
3 spontaneous erections during the follow-up of 18 months ⁶³. Oral PDE-5-I therapy is regarded
4 as standard of care and serves as initial reference treatment in men suffering from ED ⁶⁴⁻⁶⁶.
5
6 Both Sildenafil and Tadalafil are commonly used representatives of PDE5-I in the treatment of
7 ED with comparable safety and efficacy ⁶⁷. The management of concomitant injuries following
8 PRF includes the early diagnostics and exclusion or treatment of organic damages in order to
9 prevent or reduce the risk of ED ^{13 14 42}. According the results of our meta-analysis, the
10 treatment with PDE-5-I increases the IIEF-5 score by 6.5 points in patients with ED after PRF
11 with urethral injury. However, it remains unclear whether it also supports the permanent
12 recovery of spontaneous erectile function. Similarly, the data for the efficacy of penile
13 rehabilitation after radical prostatectomy is still controversially discussed ^{68 69}. The effect seems
14 to be ameliorated with a regular treatment regime compared to on-demand use of PDE-5-I in
15 patients with ED after radical prostatectomy ⁷⁰. The current limited evidence demonstrates,
16 that daily oral intake of PDE-5-I seems to have also a relevant positive effect on ED in 55-88%
17 of patients after PRF with or without associated PFUI ⁷¹⁻⁷⁴. Further, the efficacy of
18 pharmacological therapy can also be supported with mechanical aids, such as the use of
19 vacuum erection devices or low-intensity shock-wave therapy. Both have shown to ameliorate
20 IIEF-5 score and erection quality when used in combination with PDE-5-I, compared to stand-
21 alone treatment ⁷⁵⁻⁷⁷. Finally, the implantation of penile prosthesis or revascularization surgery
22 are both regarded as last resort options in ED treatment of patients after perineal or pelvic
23 surgery or trauma ⁷⁸.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 Limitations & strengths

49
50 This systematic review and its meta-analysis has some limitations. Despite the strict definition
51 of PRF and ED, all of the included studies present an inevitable variability due to their
52 heterogeneous methodology and study populations coming from different centers worldwide.
53 Therefore and due to the lack of standardization, a broad variety of PRF classifications and
54 different definitions as well as questionnaires for the evaluation of ED were used. Further, all
55
56
57
58
59
60

1
2
3 of the included studies provide a considerable risk of bias (*Figure 4*). In addition, there are
4 general limitations to systematic reviews regarding the search algorithm and the potential to
5 miss relevant articles (selection bias, publication bias, language bias, time lag bias, etc.).
6
7 However, all of the included studies showed consistent and overall comparable outcomes,
8
9 which implicates a representative cohort with reliable and repeatable results included in this
10
11 analysis.
12
13
14
15
16
17

18 **Conclusion**

19
20
21 Patients who suffer from PRF have an increased risk of developing ED, regardless of the
22
23 classification severity and the concomitant injuries. Early beginning of penile rehabilitation with
24
25 the pharmacological help of PDE-5-I on a daily basis and a treatment duration of at least 3
26
27 months may relevantly reduce ED after PRF and therefore ameliorate QoL in these patients.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We thank Dr. sc. nat. Martina Gosteli, scientific librarian at the main library from the University of Zurich (Switzerland), for her precious efforts in performing a profound systematic literature research regarding the topic.

Ethics approval statement

Not applicable.

Conflicts of interest

None of the authors has any conflicts of interest to declare

Funding

No external funding sources were utilized in conducting and completing this study.

Author Statement

FAS and SH contributed equally to this work: They developed the research idea and led the research team; both authors screened independently all articles, and found consent in cases of disagreement, both authors extracted and analyzed the data; They wrote the original draft of the manuscript

UH supported and supervised the methodology and the statistical analysis of the meta data;

UH read and reviewed the manuscript critically

DE and HCP supervised the entire project, provided the infrastructure for conducting this research and critically reviewed the manuscript

Data Availability Statement

Extra data can be accessed via the Dryad data repository at <http://datadryad.org/> with the

doi: 10.5061/dryad.mpg4f4r06

References

1. Almahmoud K, Pfeifer R, Al-Kofahi K, et al. Impact of pelvic fractures on the early clinical outcomes of severely injured trauma patients. *Eur J Trauma Emerg Surg* 2018;44(2):155-62. doi: 10.1007/s00068-016-0754-6
2. Pape HC, Zelle B, Lohse R, et al. Evaluation and outcome of patients after polytrauma--can patients be recruited for long-term follow-up? *Injury* 2006;37(12):1197-203. doi: 10.1016/j.injury.2006.07.032
3. Aaran LHC, Him CK, Bong LK, et al. Outcome of Haemodynamically Unstable Open Pelvic Fracture Patients Managed With "3-in-1" Pelvic Damage Control Protocol in a Major Trauma Centre. *J Orthop Trauma Rehabil* 2018;25:62-68. doi: 10.1016/j.jotr.2017.10.002
4. Mann SM, Banaszek D, Lajkosz K, et al. High-energy trauma patients with pelvic fractures: Management trends in Ontario, Canada. *Injury-Int J Care Inj* 2018;49(10):1830-40. doi: 10.1016/j.injury.2018.06.044
5. Matityahu A, Marmor M, Elson JK, et al. Acute complications of patients with pelvic fractures after pelvic angiographic embolization. *Clinical Orthopaedics & Related Research*;471(9):2906-11.
6. Giannoudis PV, Pape HC. Damage control orthopaedics in unstable pelvic ring injuries. *Injury-Int J Care Inj* 2004;35(7):671-77. doi: 10.1016/j.injury.2004.03.003
7. Stahel PF, Burlew CC, Moore EE. Current trends in the management of hemodynamically unstable pelvic ring injuries. *Curr Opin Crit Care* 2017;23(6):511-19. doi: 10.1097/MCC.0000000000000454 [published Online First: 2017/11/03]
8. Papakostidis C, Kanakaris NK, Kontakis G, et al. Pelvic ring disruptions: treatment modalities and analysis of outcomes. *Int Orthop* 2009;33(2):329-38. doi: 10.1007/s00264-008-0555-6 [published Online First: 2008/05/08]
9. Kuper MA, Trulson A, Stuby FM, et al. Pelvic ring fractures in the elderly. *EFORT Open Rev* 2019;4(6):313-20. doi: 10.1302/2058-5241.4.180062 [published Online First: 2019/07/18]
10. Handoll HHG, Cameron ID, Mak JCS, et al. Multidisciplinary rehabilitation for older people with hip fractures. *Cochrane Database Syst Rev* 2009(4):77. doi: 10.1002/14651858.CD007125.pub2
11. Strasser DC, Uomoto JM, Smits SJ. The interdisciplinary team and polytrauma rehabilitation: Prescription for partnership. *Archives of Physical Medicine and Rehabilitation* 2008;89(1):179-81. doi: 10.1016/j.apmr.2007.06.774
12. Blaschko SD, Sanford MT, Schlomer BJ, et al. The incidence of erectile dysfunction after pelvic fracture urethral injury: A systematic review and meta-analysis. *Arab J Urol* 2015;13(1):68-74. doi: 10.1016/j.aju.2014.09.004 [published Online First: 2015/05/29]
13. Johnsen NV, Kaufman MR, Dmochowski RR, et al. Erectile Dysfunction Following Pelvic Fracture Urethral Injury. *Sex Med Rev* 2018;6(1):114-23. doi: 10.1016/j.sxmr.2017.06.004 [published Online First: 2017/08/02]
14. Horiguchi A. Management of male pelvic fracture urethral injuries: Review and current topics. *Int J Urol* 2019;26(6):596-607. doi: 10.1111/iju.13947
15. Shamloul R, Ghanem H. Erectile dysfunction. *Lancet* 2013;381(9861):153-65. doi: 10.1016/S0140-6736(12)60520-0 [published Online First: 2012/10/09]
16. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*

- 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097 [published Online First: 2009/07/22]
17. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;350:g7647. doi: 10.1136/bmj.g7647 [published Online First: 2015/01/04]
 18. Burgess AR, Eastridge BJ, Young JW, et al. Pelvic ring disruptions: effective classification system and treatment protocols. *J Trauma* 1990;30(7):848-56. [published Online First: 1990/07/01]
 19. Tile M. Acute Pelvic Fractures: I. Causation and Classification. *J Am Acad Orthop Surg* 1996;4(3):143-51. doi: 10.5435/00124635-199605000-00004 [published Online First: 1996/05/01]
 20. Meinberg EG, Agel J, Roberts CS, et al. Fracture and Dislocation Classification Compendium-2018. *J Orthop Trauma* 2018;32 Suppl 1:S1-S170. doi: 10.1097/BOT.0000000000001063 [published Online First: 2017/12/20]
 21. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. *Urology* 1997;49(6):822-30. doi: 10.1016/s0090-4295(97)00238-0 [published Online First: 1997/06/01]
 22. Rhoden EL, Teloken C, Sogari PR, et al. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. *Int J Impot Res* 2002;14(4):245-50. doi: 10.1038/sj.ijir.3900859 [published Online First: 2002/08/02]
 23. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. *Int J Impot Res* 1999;11(6):319-26. doi: 10.1038/sj.ijir.3900472 [published Online First: 2000/01/19]
 24. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. *Syst Rev* 2016;5(1):210. doi: 10.1186/s13643-016-0384-4 [published Online First: 2016/12/07]
 25. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011;155(8):529-36. doi: 10.7326/0003-4819-155-8-201110180-00009 [published Online First: 2011/10/19]
 26. Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.0 (updated July 2019). *Cochrane* 2019
 27. Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014;14:135. doi: 10.1186/1471-2288-14-135 [published Online First: 2014/12/20]
 28. Luo D, Wan X, Liu J, et al. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. *Stat Methods Med Res* 2018;27(6):1785-805. doi: 10.1177/0962280216669183 [published Online First: 2016/09/30]
 29. Weir CJ, Butcher I, Assi V, et al. Dealing with missing standard deviation and mean values in meta-analysis of continuous outcomes: a systematic review. *BMC Med Res Methodol* 2018;18(1):25. doi: 10.1186/s12874-018-0483-0 [published Online First: 2018/03/09]

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
30. R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing V, Austria. URL <https://www.R-project.org/>. [
31. Fanjalalaina Ralahy M, R P, riantsoa M, et al. Incidence of erectile dysfunction in pelvic ring injuries: Study of 48 patients at the Antananarivo hospital, Madagascar. *Orthopaedics & traumatology, surgery & research*;105(5):885-88.
32. Pastor T, Tiziani S, Kasper CD, et al. Quality of reduction correlates with clinical outcome in pelvic ring fractures. *Injury-Int J Care Inj* 2019;50(6):1223-26. doi: 10.1016/j.injury.2019.04.015
33. Schmitz P, Ludeck S, Baumann F, et al. Patient-related quality of life after pelvic ring fractures in elderly. *Int Orthop* 2019;43(2):261-67. doi: 10.1007/s00264-018-4030-8 [published Online First: 2018/06/28]
34. Brouwers L, Lansink KWW, de Jongh MAC. Quality of life after pelvic ring fractures: A cross-sectional study. *Injury* 2018;49(4):812-18. doi: 10.1016/j.injury.2018.03.012 [published Online First: 2018/03/24]
35. Montgomery B, Husmann D. Pelvic fracture urethral distraction defect (PFUDD) with associated rectal injury: A review of acute and definitive urologic management with long term outcomes. *J Urol* 2016;195(4):e1000.
36. Gdeh D, Haffejee M, Nel M. Frequency of Erectile Dysfunction Following Pelvic Fracture among Patients Admitted to Two Wits Teaching Hospitals, South Africa. *Sudan Journal of Medical Sciences* 2018;13(3):144-67.
37. King J. Impotence after fractures of the pelvis. *Journal of Bone & Joint Surgery - American Volume*;57(8):1107-9.
38. Metze M, Tiemann AH, Josten C. Male sexual dysfunction after pelvic fracture. *Journal of Trauma-Injury Infection & Critical Care*;63(2):394-401.
39. Yafi FA, Huynh LM, Ahlering T, et al. What Is a "Validated Questionnaire"? A Critical Review of Erectile Function Assessment. *J Sex Med* 2020;17(5):849-60. doi: 10.1016/j.jsxm.2020.02.005 [published Online First: 2020/03/09]
40. Ceylan HH, Kuyucu E, Erdem R, et al. Does pelvic injury trigger erectile dysfunction in men? *Chinese Journal of Traumatology* 2015;18(4):229-31.
41. Duramaz A, Ilter MH, Yildiz S, et al. The relationship between injury mechanism and sexual dysfunction in surgically treated pelvic fractures. *Eur J Trauma Emerg Surg* 2020;46(4):807-16. doi: 10.1007/s00068-018-01067-0 [published Online First: 2019/01/09]
42. Harwood PJ, Grotz M, Eardley I, et al. Erectile dysfunction after fracture of the pelvis. *J Bone Joint Surg Br* 2005;87(3):281-90. doi: 10.1302/0301-620x.87b3.15662 [published Online First: 2005/03/19]
43. Armenakas NA, McAninch JW, Lue TF, et al. Posttraumatic impotence: magnetic resonance imaging and duplex ultrasound in diagnosis and management. *J Urol* 1993;149(5 Pt 2):1272-5. doi: 10.1016/s0022-5347(17)36365-6 [published Online First: 1993/05/01]
44. Robinson LQ, Woodcock JP, Stephenson TP. Results of investigation of impotence in patients with overt or probable neuropathy. *Br J Urol* 1987;60(6):583-7. doi: 10.1111/j.1464-410x.1987.tb05046.x [published Online First: 1987/12/01]
45. Ellison M, Timberlake GA, Kerstein MD. Impotence following pelvic fracture. *Journal of Trauma-Injury Infection & Critical Care*;28(5):695-6.
46. Shenfeld OZ, Kiselgorf D, Gofrit ON, et al. The incidence and causes of erectile dysfunction after pelvic fractures associated with posterior urethral disruption. *J Urol*;169(6):2173-6.

- 1
- 2
- 3 47. Munarriz RM, Yan QR, A ZN, et al. Blunt trauma: the pathophysiology of
- 4 hemodynamic injury leading to erectile dysfunction. *J Urol* 1995;153(6):1831-
- 5 40. doi: 10.1016/s0022-5347(01)67324-5 [published Online First: 1995/06/01]
- 6
- 7 48. Mark SD, Keane TE, emark RM, et al. Impotence following pelvic fracture urethral
- 8 injury: incidence, aetiology and management. *British Journal of*
- 9 *Urology*;75(1):62-4.
- 10
- 11 49. Blaschko SD, Sanford MT, Schlomer BJ, et al. The incidence of erectile dysfunction
- 12 after pelvic fracture urethral injury: A systematic review and meta-analysis. *Arab*
- 13 *Journal of Urology Print*;13(1):68-74.
- 14
- 15 50. Anger JT, Sherman ND, Dielubanza E, et al. Erectile function after posterior
- 16 urethroplasty for pelvic fracture-urethral distraction defect injuries. *BJU*
- 17 *Int*;104(8):1126-9.
- 18
- 19 51. Johnsen NV, Kaufman MR, Dmochowski RR, et al. Erectile Dysfunction Following
- 20 Pelvic Fracture Urethral Injury. *Sexual Medicine Reviews*;6(1):114-23.
- 21
- 22 52. Barratt RC, Bernard J, Mundy AR, et al. Pelvic fracture urethral injury in males-
- 23 mechanisms of injury, management options and outcomes. *Translational*
- 24 *Andrology & Urology*;7:S29-S62.
- 25
- 26 53. Light A, Gupta T, Dadabhoy M, et al. Outcomes Following Primary Realignment
- 27 Versus Suprapubic Cystostomy with Delayed Urethroplasty for Pelvic Fracture-
- 28 Associated Posterior Urethral Injury: A Systematic Review with Meta-Analysis.
- 29 *Current Urology*;13(3):113-24.
- 30
- 31 54. Scarberry K, Bonomo J, Gomez RG. Delayed Posterior Urethroplasty Following
- 32 Pelvic Fracture Urethral Injury: Do We Have to Wait 3 Months?
- 33 *Urology*;116:193-97.
- 34
- 35 55. Zou Q, Zhou S, Zhang K, et al. The Immediate Management of Pelvic Fracture
- 36 Urethral Injury-Endoscopic Realignment or Cystostomy? *J Urol*;198(4):869-74.
- 37
- 38 56. Rey VM, Fernandez C, Zanabili A, et al. Endovascular Repair of Iliac Vein
- 39 Laceration Associated with Complex Pelvic Fracture. *Ann Vasc Surg* 2019;54:4.
- 40 doi: 10.1016/j.avsg.2018.06.020
- 41
- 42 57. Baca V, Bacova T, Grill R, et al. Pudendal nerve in pelvic bone fractures. *Injury*
- 43 2013;44(7):952-56. doi: 10.1016/j.injury.2012.12.004 [published Online First:
- 44 2013/02/07]
- 45
- 46 58. Wright JL, Nathens AB, Rivara FP, et al. Specific fracture configurations predict
- 47 sexual and excretory dysfunction in men and women 1 year after pelvic fracture.
- 48 *J Urol*;176(4):1540-5; discussion 45.
- 49
- 50 59. Wright JL, Wessells HB, Nathens AB, et al. Sexual and excretory dysfunction one
- 51 year after pelvic fracture. *J Urol*;173(4):91-91.
- 52
- 53 60. Harvey-Kelly KF, Kanakaris NK, Obakponovwe O, et al. Quality of life and sexual
- 54 function after traumatic pelvic fracture. *Journal of Orthopaedic*
- 55 *Trauma*;28(1):28-35.
- 56
- 57 61. Harvey-Kelly KF, Kanakaris NK, Eardley I, et al. Sexual function impairment after
- 58 high energy pelvic fractures: evidence today. *J Urol*;185(6):2027-34.
- 59
- 60 62. Delle Rose A, Stomaci N, Pironti M, et al. Impotence due to pelvic trauma:
- Treatment with papaverine and PGE1. *Acta Urologica Italica* 1992;6:27-28.
63. Shenfeld OZ, Gofrit ON, Gdor Y, et al. The role of sildenafil in the treatment of
- erectile dysfunction in patients with pelvic fracture urethral disruption. *J*
- Urol*;172(6):2350-2.
64. Ventimiglia E, Capogrosso P, Montorsi F, et al. The safety of phosphodiesterase
- type 5 inhibitors for erectile dysfunction. *Expert Opin Drug Saf* 2016;15(2):141-
52. doi: 10.1517/14740338.2016.1131818 [published Online First: 2016/01/12]

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
65. Goldstein I, Tseng LJ, Creanga D, et al. Efficacy and Safety of Sildenafil by Age in Men With Erectile Dysfunction. *J Sex Med* 2016;13(5):852-9. doi: 10.1016/j.jsxm.2016.02.166 [published Online First: 2016/04/27]
66. Liao X, Qiu S, Bao Y, et al. Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials. *World J Urol* 2019;37(6):1061-74. doi: 10.1007/s00345-018-2583-1 [published Online First: 2018/12/14]
67. Gong B, Ma M, Xie W, et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. *Int Urol Nephrol* 2017;49(10):1731-40. doi: 10.1007/s11255-017-1644-5 [published Online First: 2017/07/26]
68. Liu C, Lopez DS, Chen M, et al. Penile Rehabilitation Therapy Following Radical Prostatectomy: A Meta-Analysis. *J Sex Med* 2017;14(12):1496-503. doi: 10.1016/j.jsxm.2017.09.020 [published Online First: 2017/11/11]
69. Philippou YA, Jung JH, Steggall MJ, et al. Penile rehabilitation for postprostatectomy erectile dysfunction. *Cochrane Database Syst Rev* 2018;10:CD012414. doi: 10.1002/14651858.CD012414.pub2 [published Online First: 2018/10/24]
70. Qiu S, Tang Z, Deng L, et al. Comparisons of regular and on-demand regimen of PDE5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer. *Sci Rep* 2016;6:32853. doi: 10.1038/srep32853 [published Online First: 2016/09/10]
71. Nieto-Esquivel A, Delgado-Balderas R, Robles-Torres JI, et al. [Use of tadalafil in the rehabilitation of patients with a history of posterior urethral injury in the context of pelvic fracture]. *Revista Internacional de Andrologia*;16(1):15-19.
72. Fu Q, Sun X, Tang C, et al. An assessment of the efficacy and safety of sildenafil administered to patients with erectile dysfunction referred for posterior urethroplasty: a single-center experience. *J Sex Med*;9(1):282-7.
73. Peng J, Zhang Z, Gao B, et al. Effect of daily sildenafil on patients with absent nocturnal erections due to pelvic fracture urethral disruption: A singlecenter experience. *J Sex Med* 2017;14(1):S25.
74. Qiang F, Xianjun S, Chenye T, et al. The efficacy and safety of sildenafil on treatment of patients with erectile dysfunction referred for posterior urethroplasty: A single center experience. *Chinese Journal of Andrology* 2011;25(8):27-31.
75. Wang CJ, Lu YM, Li CC, et al. Low-intensity shock wave therapy ameliorates erectile dysfunction in men with pelvic fractures associated with urethral injury. *Int J Impot Res*;31(3):218-22.
76. Zhang DL, Chen Z, Wang FX, et al. Adding a vacuum erection device to regular use of Tadalafil improves penile rehabilitation after posterior urethroplasty. *Asian J Androl*;21(6):582-86.
77. Song L, Fu Q. The role of vacuum erection devices in penile rehabilitation after posterior urethral anastomotic urethroplasty:A pilot study. *J Urol* 2017;197(4):e1224-e25.
78. Hellstrom WJ, Montague DK, Moncada I, et al. Implants, mechanical devices, and vascular surgery for erectile dysfunction. *J Sex Med* 2010;7(1 Pt 2):501-23. doi: 10.1111/j.1743-6109.2009.01626.x [published Online First: 2010/01/23]

Figures Legend

Figure 1

PRISMA flow diagram of study selection

Figure 2

Weighted forest plot displaying the proportion of patients developing ED according to PRF classification.

Abbreviations: ABC = Tile A, B and C fractures; APC = anteroposterior compression, LC = lateral compression and VS = vertical shear according Young & Burgess; PFUI = pelvic fracture urethral injury.

Figure 3

Forest plot displaying the treatment effect as mean change score between IIEF-5 scores before and after penile rehabilitation treatment with PDE-5-I.

Abbreviations: PFUI = pelvic fracture urethral injury.

Figure 4


Domains in risk of bias of all included studies according to QUADAS-2 tool. Traffic light plot (A) and weighted summary plot (B).

Table 1: Included articles

Author	Year	Country	Study Design	n	mean age (range)	Inclusion	Main result
Nieto	2017	Mexico	Retrospective Cohort Study	8	32.5 (26 - 56)	Treatment effect PDE-5-I	Nearly all patients (87.5%) had a positive effect on IIEF-5 questionnaires after penile rehabilitation treatment with Tadalafil 5mg for 3 months.
Peng	2014	China	Retrospective Cohort Study	31	33.1 (26 - 46)	Treatment effect PDE-5-I	More than half of the patients (54.8%) reported a successful penile rehabilitation with better IIEF-5 score after 3 months treatment with Sildenafil 50mg.
Peng	2015	China	NFS	28	34 (22 - 49)	Treatment effect PDE-5-I	Almost two-thirds of the patients (61.5%) witnessed a positive effect on IIEF-5 scores after penile rehabilitation with Sildenafil 50mg for 3 months.
Chung	2018	USA	Retrospective Cohort Study	29	52 (18 - >70)	Incidence of ED after PRF	ED was reported in 47.5% of all patients following PRF according to IIEF-5 scores.
Duramaz	2019	Turkey	Retrospective Cohort Study	52	35 (19 - 50)	Incidence of ED after PRF	Vertical shear injuries were the most common type of PRF in patients who suffered ED according to IIEF-5 scores.
Fanjala	2019	Madagascar	Retrospective Cohort Study	42	39.6 (18 - >66)	Incidence of ED after PRF	One in three patients (33.3%) suffered ED following PRF according to IIEF-5 scores.
Malavaud	2000	France	Retrospective Cohort Study	37	37.8 (16 - 76)	Incidence of ED after PRF	Nearly one in three patients (29.7%) reported ED following PRF according to IIEF-5 scores.
n = number of patients NFS = Not further specified IIEF-5 = International Index of Erectile Function 5 Questionnaire PDE-5-I = Phosphodiesterase 5 inhibitor PRF = Pelvic ring fracture ED = Erectile dysfunction							

Figure 1: PRISMA flow diagram of study selection


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



BMJ Open: first published as 10.1136/bmjopen-2020-025117 on 28 May 2021. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59


Injury	Author	Year	Country	N	Months of Follow-up	Proportion [95% CI]
ABC	Malavaud	2000	France	37	26.8	0.30 [0.17, 0.46]
A	Fanjalalaina	2019	Madagascar	29	12.5	0.24 [0.12, 0.43]
B	Fanjalalaina	2019	Madagascar	8	12.5	0.62 [0.28, 0.87]
C	Fanjalalaina	2019	Madagascar	5	12.5	0.80 [0.31, 0.97]
APC	Duramaz	2019	Turkey	12	27	0.42 [0.18, 0.69]
LC	Duramaz	2019	Turkey	20	27	0.02 [0.00, 0.29]
VS	Duramaz	2019	Turkey	20	27	0.40 [0.21, 0.62]
no_PFUI	Chung	2018	USA	21	56.4	0.38 [0.20, 0.60]
PFUI	Chung	2018	USA	29	46.8	0.59 [0.40, 0.75]
RE Model	(Q = 18.01, p = 0.021; I ² = 44.2%, H ² = 1.8)			181		0.37 [0.26, 0.50]



BMJ Open: first published as 10.1136/bmjopen-2020-025117 on 28 May 2021. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

Author, Year	Injury	Country	N	Treatment	Months of Treatment	IIEF-5 post-pre	Change Score [95% CI]
Nieto, 2017	PFUI	Mexico	8	Tadalafil, 5mg	3		10.75 [8.04, 13.46]
Peng, 2014	PFUI	China	31	Sildenafil, 50mg	3		4.00 [3.01, 4.99]
Peng, 2015	PFUI	China	28	Sildenafil, 50mg	3		5.22 [3.25, 7.19]
RE Model	(Q = 21.14, p < 0.0001; I ² = 93.0%, H ² = 14.3)		67				6.50 [2.54, 10.46]




A

Study	Risk of bias domains				
	D1	D2	D3	D4	Overall
Chung et al. (2018)	X	+	?	X	X
Duramaz et al. (2019)	+	+	X	X	X
Fanjalalaina et al. (2019)	+	+	X	+	X
Malavaud et al. (2000)	+	+	X	X	X
Nieto et al. (2017)	X	+	X	X	X
Peng et al. (2014)	X	+	?	X	X
Peng et al. (2015)	X	+	?	X	X

Domains:
 D1: Patient selection
 D2: IIEF-5 questionnaire
 D3: Fracture classification
 D4: Flow & timing

Judgement
 X High
 + Low
 ? No information

B





[Support & Training](#)

[Feedback](#)

[Close](#)

Database(s): **Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily** 1946 to January 16, 2020

Search Strategy:

#	Searches	Results
1	(exp Pelvic Bones/ and Fractures, Bone/) or exp Pelvic Bones/in or ((pelvic or pelvis or acetabular or acetabulum) adj3 (fracture* or trauma*)).ti,ab.	11058
2	exp Erectile Dysfunction/ or Penile Erection/ or (erectile adj3 (dysfunction or function or process or failure or capacity or disorder* or problem*)).ti,ab. or (sexual adj3 dysfunction).ti,ab. or (erection or impotence or 'iief').ti,ab.	39893
3	1 and 2	293
4	exp Erectile Dysfunction/rh, th or (rehab* or therap* or treat*).mp.	8890204
5	3 and 4	182

1. Etiology of **Erectile Dysfunction** and Duration of Symptoms in Patients Undergoing Penile Prosthesis: A Systematic Review. [Review]

Bajic P; Mahon J; Faraday M; Sadeghi-Nejad H; Hakim L; McVary KT.

Sexual Medicine Reviews. 2019 Jul 02.

[Journal Article. Review]

UI: 31278064

Authors Full Name

Bajic, Petar; Mahon, Joseph; Faraday, Martha; Sadeghi-Nejad, Hossein; Hakim, Lawrence; McVary, Kevin T.

1 Embase®

2
3
4
5 Embase Session Results (17 Jan 2020)

6
7
8

9 No.	Query	Results
10 #6	#3 NOT #5	146
12 #5	#3 AND #4	270
14 #4	'erectile dysfunction'/exp/dm_dm,dm_dt,dm_rh,dm_th OR rehab*:ti,ab,de OR therap*:ti,ab,de OR treat*:ti,ab,de	11040498
16 #3	#1 AND #2	416
18 #2	'erectile dysfunction'/exp OR 'penis erection'/exp OR 'international index of erectile function'/exp OR ((erectile NEAR/3 (dysfunction OR function OR process OR failure OR capacity OR disorder* OR problem*)):ti,ab) OR ((sexual NEAR/3 dysfunction):ti,ab) OR erection:ti,ab OR impotence:ti,ab OR 'iief':ti,ab	65289
21 #1	('pelvis fracture'/exp OR (((pelvic OR pelvis OR acetabular OR acetabulum) NEAR/3 (fracture* OR trauma*)):ti,ab)) NOT ([conference abstract]/lim AND [1974-2014]/py)	12784

23
24
25
26
27
28
29
30

31
32 ELSEVIER

33 © 2020 Elsevier Life Sciences IP Limited except certain content provided
34 by third parties.

35 Embase is a trade mark of Elsevier Life Sciences IP Limited. RELX Group
36 and the RE symbol are trade marks of RELX Group plc, used under
37 license.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Cookies ✕
 Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in About Cookies.



Access provided by: **UZH Hauptbibliothek / Zentralbibliothek Zürich**

Advanced Search

<input type="button" value="−"/>	<input text"="" type="button" value="#1"/>	<input type="text" value="((pelvic OR pelvis OR acetabular OR acetabulum) NEAR/3 (fracture* OR trauma*)):ti,ab,kw"/>	<input type="button" value="Limits"/>	<input type="text" value="382"/>		
<input type="button" value="−"/>	<input text"="" type="button" value="#2"/>	<input type="text" value="(erectile NEAR/3 (dysfunction OR function OR process OR failure OR capacity OR disorder* OR problem*)):ti,ab,kw OR (sexual NEAR/3 dysfunction):ti,ab,kw OR (erection OR impotence OR iief):ti,ab,kw"/>	<input type="button" value="Limits"/>	<input type="text" value="6630"/>		
<input type="button" value="−"/>	<input text"="" type="button" value="#3"/>	<input type="text" value="#1 AND #2"/>	<input type="button" value="Limits"/>	<input type="text" value="16"/>		
<input type="button" value="−"/>	<input text"="" type="button" value="#4"/>	<input type="text" value="Type a search term or use the S or MeSH buttons to compose"/>	<input type="button" value="S"/>	<input type="button" value="MeSH"/>	<input type="button" value="Limits"/>	<input type="text" value="N/A"/>

Highlight orphan lines

Cochrane Reviews 0	Cochrane Protocols 0	Trials 16	Editorials 0	Special collections 0	Clinical Answers 0	Other Reviews
-----------------------	-------------------------	----------------------	-----------------	--------------------------	-----------------------	---------------

16 Trials matching "**#3 - #1 AND #2**"

Cochrane Central Register of Controlled Trials
 Issue 1 of 12, January 2020

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Deselect all (16) Export selected citation(s)

Order by Relevancy ▾ Results per page 25 ▾

1

Vardenafil and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV)
 NCT02450188
<https://clinicaltrials.gov/show/NCT02450188>, 2014 | added to CENTRAL: 31 Mai 2018 | 2018 Issue 5
 CT.gov

2

Erectile function improvement with oral sildenafil versus placebo in posterior urethroplasty: double blind randomized controlled trial
 MM Mazloomfard, J Hosseini, M Jabbari
 International journal of urology, 2014, 21, A257-A258 | added to CENTRAL: 31 März 2015 | 2015 Issue 3
 Embase

3

The role of vacuum erection devices in penile rehabilitation after posterior urethral anastomotic urethroplasty; A pilot study
 L Song, T Liu, Q Fu
 Journal of sexual medicine, 2017, 14(1), S29- | added to CENTRAL: 31 Januar 2018 | 2018 Issue 1
 Embase

4

The role of vacuum erection devices in penile rehabilitation after posterior urethral anastomotic urethroplasty: a pilot study
 L Song, Q Fu
 Journal of urology, 2017, 197(4), e1224-e1225 | added to CENTRAL: 30 Juni 2017 | 2017 Issue 6
 Embase

5

The role of vacuum erection devices in penile rehabilitation after posterior urethral anastomotic urethroplasty: a pilot study
 L Song, T Liu, Q Fu
 International journal of urology. Conference: 14th asian congress of urology of the urological association of asia, ACU 2016. Singapore singapore. Conference start: 20160720. Conference end: 20160724. Conference publication: (var.pagings), 2016, 23, 6 | added to CENTRAL: 31 Mai 2018 | 2018 Issue 5
 Embase

6

Comparison of Subcutaneous INFIX and EXFIX for Anterior Pelvic Ring Fractures Requiring Stabilization
 NCT02403154
<https://clinicaltrials.gov/show/NCT02403154>, 2015 | added to CENTRAL: 31 Mai 2018 | 2018 Issue 5
 CT.gov

7

-

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Reconstructive surgery, primary realignment

F Mirkazemi

International journal of urology, **2014**, 21, A59- | added to CENTRAL: 31 März 2015 | 2015 Issue 3

Embase

8 **A preliminary clinical study on non-transecting urethroplasty for the treatment of posterior urethral stricture caused by pelvic fractures**

ChiCTR-INR-16010132

http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-INR-16010132, **2016** | added to CENTRAL: 31 März 2019 | 2019 Issue 3

ICTRP

9 **Not applicable**

EUCTR2011-005333-39-GR

http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011-005333-39-GR, **2011** | added to CENTRAL: 31 März 2019 | 2019 Issue 3

ICTRP

10 **Primary Urethral Realignment Versus Suprapubic Cystostomy After Pelvic Fracture Urethral Injury**

NCT03195179

https://clinicaltrials.gov/show/NCT03195179, **2017** | added to CENTRAL: 31 Mai 2018 | 2018 Issue 5

CT.gov

11 **Is on demand use of tramadol more effective than selective serotonin reuptake inhibitors and/or sildenafil and/or topical penile anesthetics in treating premature ejaculation (PE)?**

V Boulos, A Hassanin, MF Roaiah

European urology, supplements., **2015**, 14(2), e242 | added to CENTRAL: 31 August 2015 | 2015 Issue 8

Embase

12 **Preexisting vascular pathology in donor and recipient vessels during penile microvascular arterial bypass surgery**

DG Hatzichristou, I Goldstein, WC Quist

Journal of urology, **1994**, 151(5), 1217-1224 | added to CENTRAL: 31 März 2019 | 2019 Issue 3

PubMed | Embase

13 **Surgical management for Chinese children urethral injury: a systematic review**

B-S Gong, G-B Xiong, M-X Qiu

Chinese journal of evidence-based medicine, **2010**, 10(9), 1063-1071 | added to CENTRAL: 31 März 2019 | 2019 Issue 3

Embase

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

14

Comparison of the effect of two intervention methods (pelvic floor exercise and moisturizing cream) on sexual function and disparity in women undergoing systemic cancer

IRCT20190619043952N1

<http://www.who.int/trialssearch/Trial2.aspx?TrialID=IRCT20190619043952N1>, 2019 | added to CENTRAL: 30 September 2019 | 2019 Issue 09

[ICTRP](#)

15

Relationship of episiotomy to perineal trauma and morbidity, sexual dysfunction, and pelvic floor relaxation

MC Klein, RJ Gauthier, JM Robbins, J Kaczorowski, SH Jorgensen, ED Franco, B Johnson, K Waghorn, MM Gelfand, MS Guralnick

American journal of obstetrics and gynecology, 1994, 171(3), 591-598 | added to CENTRAL: 31 Januar 1998 | 1998 Issue 1

[PubMed](#)

16

A Phase II study of acute toxicity for Celebrex™ (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128

DK Gaffney, K Winter, AP Dicker, B Miller, PJ Eifel, J Ryu, V Avizonis, M Fromm, K Greven

International journal of radiation oncology biology physics, 2007, 67(1), 104-109 | added to CENTRAL: 31 März 2019 | 2019 Issue 3

[PubMed](#) [Embase](#)

Web of Science

Search Tools Searches and alerts Search History Marked List

Search History

Web of Science Core Collection

Set	Results	Save History / Create Alert	Open Saved History	Edit Sets	Combine Sets AND OR Combine	Delete Sets Select All Delete
# 6	139	#3 not #5 <i>Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=All years</i>		Edit		
# 5	150	#4 AND #3 <i>Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=All years</i>		Edit		
# 4	7,584,849	TS=(rehab* OR therap* OR treat*) <i>Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=All years</i>		Edit		
# 3	289	#2 AND #1 <i>Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=All years</i>		Edit		
# 2	46,855	TS=(erectile NEAR/3 (dysfunction OR function OR process OR failure OR capacity OR disorder* OR problem*)) OR TS=(sexual NEAR/3 dysfunction) OR TS=(erection OR impotence OR iief) <i>Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=All years</i>		Edit		
# 1	7,712	TS=((pelvic OR pelvis OR acetabular OR acetabulum) NEAR/3 (fracture* OR trauma*)) <i>Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=All years</i>		Edit		
					AND OR Combine	Select All Delete

Clarivate
Accelerating innovation

© 2020 Clarivate
Copyright notice
Terms of use
Privacy statement
Cookie policy

Sign up for the Web of Science newsletter
Follow us

Brought to you by [UZH Hauptbibliothek / Zentralbibliothek Zürich](#)

Elsevier logo Scopus

Search

Sources

Lists

SciVal

Help

Alerts

Institu

Create account

Sign in

Advanced search

Compare sources

Documents Authors Affiliations Advanced

Search tips

Enter query string

(TITLE-ABS-KEY(((pelvic OR pelvis OR acetabular OR acetabulum) W/3 (fracture* OR trauma*))) AND (TITLE-ABS-KEY(erectile W/3 (dysfunction OR function OR process OR failure OR capacity OR disorder* OR problem*))) OR TITLE-ABS-KEY(sexual W/3 dysfunction) OR TITLE-ABS-KEY(erection OR impotence OR iief))

Add Author name / Affiliation Clear form

ALL("Cognitive architectures") AND AUTHOR-NAME(smith)
TITLE-ABS-KEY(*somatic complaint wom?n) AND PUBYEAR AFT 1993
SRCTITLE(*field ornith*) AND VOLUME(75) AND ISSUE(1) AND PAGES(53-66)

Operators

- AND
- OR
- AND NOT
- PRE/
- W/

Field codes

- Textual Content
- Affiliations
- Authors
- Biological Entities
- Chemical Entities
- Conferences
- Document
- Editors
- Funding

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

6/bmjopen-2020-045117 on 28 May 2021. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

- Keywords
- Publication
- References
- Subject Areas

Search history

Combine queries...

e.g. #1 AND NOT #3



6	((TITLE-ABS-KEY ((pelvic OR pelvis OR acetabular OR acetabulum) W/3 (fracture* OR trauma*))) AND (TITLE-ABS-KEY (erectile W/3 (dysfunction OR function OR process OR failure OR capacity OR disorder* OR problem*)) OR TITLE-ABS-KEY (sexual W/3 dysfunction) OR TITLE-ABS-KEY (erection OR impotence OR iief))) AND NOT (TITLE-ABS-KEY (rehab* OR therap* OR treat*))	158 document results	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
5	((TITLE-ABS-KEY ((pelvic OR pelvis OR acetabular OR acetabulum) W/3 (fracture* OR trauma*))) AND (TITLE-ABS-KEY (erectile W/3 (dysfunction OR function OR process OR failure OR capacity OR disorder* OR problem*)) OR TITLE-ABS-KEY (sexual W/3 dysfunction) OR TITLE-ABS-KEY (erection OR impotence OR iief))) AND (TITLE-ABS-KEY (rehab* OR therap* OR treat*))	306 document results	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
4	TITLE-ABS-KEY (rehab* OR therap* OR treat*)	12,028,602 document results	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
3	(TITLE-ABS-KEY ((pelvic OR pelvis OR acetabular OR acetabulum) W/3 (fracture* OR trauma*))) AND (TITLE-ABS-KEY (erectile W/3 (dysfunction OR function OR process OR failure OR capacity OR disorder* OR problem*)) OR TITLE-ABS-KEY (sexual W/3 dysfunction) OR TITLE-ABS-KEY (erection OR impotence OR iief))	464 document results	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
2	TITLE-ABS-KEY (erectile W/3 (dysfunction OR function OR process OR failure OR capacity OR disorder* OR problem*)) OR TITLE-ABS-KEY (sexual W/3 dysfunction) OR TITLE-ABS-KEY (erection OR impotence OR iief)	87,771 document results	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

6/bmjopen-2020-045117 on 28 May 2021. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

[Help improve Scopus](#)

About Scopus

- [What is Scopus](#)
- [Content coverage](#)
- [Scopus blog](#)
- [Scopus API](#)
- [Privacy matters](#)

Language

- [日本語に切り替える](#)
- [切换到简体中文](#)
- [切换到繁體中文](#)
- [Русский язык](#)

Customer Service

- [Help](#)
- [Contact us](#)

[Terms and conditions](#) [Privacy policy](#)

Copyright © [Elsevier B.V.](#) . All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the [use of cookies](#).





PRISMA 2020 Checklist

1136/bmjopen-2020-045117 on 28 May 2021. Downloaded from <http://bmjopen.bmj.com/> by guest. Protected by copyright.

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Page 1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Page 2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page 4
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 4
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Page 5/6
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Page 5
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Supplement
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Page 6
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Page 7
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Page 7
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Page 7
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Page 7
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Page 7/8
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Page 7/8
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Page 7/8
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Page 7/8
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Page 7/8
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Page 7/8
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Page 7/8
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting bias).	Page 7
Certainty	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Page 7/8



PRISMA 2020 Checklist

assessment			
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Page 9
Study characteristics	17	Cite each included study and present its characteristics.	Table 1
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Figure 4
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Figures 2 and 3
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Table 1
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Figure 2 and 3
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Figures 2 and 3
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Page 11
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Page 11
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Page 9/10
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Page 12
	23b	Discuss any limitations of the evidence included in the review.	Page 14/15
	23c	Discuss any limitations of the review processes used.	Page 14/15
	23d	Discuss implications of the results for practice, policy, and future research.	Page 13-16
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Page 5
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Page 5
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	Page 5
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 16
Competing interests	26	Declare any competing interests of review authors.	Page 16
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	NA

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71
For more information, visit: <http://www.prisma-statement.org/>

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



PRISMA 2020 for Abstracts Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section and Topic	Item #	Checklist item	Reported (Yes/No)
TITLE			
Title	1	Identify the report as a systematic review.	Yes
BACKGROUND			
Objectives	2	Provide an explicit statement of the main objective(s) or question(s) the review addresses.	Yes
METHODS			
Eligibility criteria	3	Specify the inclusion and exclusion criteria for the review.	Yes
Information sources	4	Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched.	Yes
Risk of bias	5	Specify the methods used to assess risk of bias in the included studies.	Yes
Synthesis of results	6	Specify the methods used to present and synthesise results.	Yes
RESULTS			
Included studies	7	Give the total number of included studies and participants and summarise relevant characteristics of studies.	Yes
Synthesis of results	8	Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured).	Yes
DISCUSSION			
Limitations of evidence	9	Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision).	Yes
Interpretation	10	Provide a general interpretation of the results and important implications.	Yes
OTHER			
Funding	11	Specify the primary source of funding for the review.	Yes
Registration	12	Provide the register name and registration number.	Yes

1136/bmjopen-2020-045117 on 28 May 2021 Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>